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ABSTRACT
Background: Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease involving loss of motor neurons
and having no known cure and uncertain etiology. Several studies have drawn connections between altered
retrotransposon expression and ALS. Certain features of the LINE-1 (L1) retrotransposon-encoded ORF1 protein (ORF1p)
are analogous to those of neurodegeneration-associated RNA-binding proteins, including formation of cytoplasmic
aggregates. In this study we explore these features and consider possible links between L1 expression and ALS.
Results: We first considered factors that modulate aggregation and subcellular distribution of LINE-1 ORF1p, including
nuclear localization. Changes to some ORF1p amino acid residues alter both retrotransposition efficiency and protein
aggregation dynamics, and we found that one such polymorphism is present in endogenous L1s abundant in the
human genome. We failed, however, to identify CRM1-mediated nuclear export signals in ORF1p nor strict involvement
of cell cycle in endogenous ORF1p nuclear localization in human 2102Ep germline teratocarcinoma cells. Some proteins
linked with ALS bind and colocalize with L1 ORF1p ribonucleoprotein particles in cytoplasmic RNA granules. Increased
expression of several ALS-associated proteins, including TAR DNA Binding Protein (TDP-43), strongly limits cell culture
retrotransposition, while some disease-related mutations modify these effects. Using quantitative reverse transcription PCR
(RT-qPCR) of ALS tissues and reanalysis of publicly available RNA-Seq datasets, we asked if changes in expression of
retrotransposons are associated with ALS. We found minimal altered expression in sporadic ALS tissues but confirmed a
previous report of differential expression of many repeat subfamilies in C9orf72 gene-mutated ALS patients.
Conclusions: Here we extended understanding of the subcellular localization dynamics of the aggregation-prone LINE-1
ORF1p RNA-binding protein. However, we failed to find compelling evidence for misregulation of LINE-1 retrotransposons
in sporadic ALS nor a clear effect of ALS-associated TDP-43 protein on L1 expression. In sum, our study reveals that the
interplay of active retrotransposons and the molecular features of ALS are more complex than anticipated. Thus, the
potential consequences of altered retrotransposon activity for ALS and other neurodegenerative disorders are worthy of
continued investigation.
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Background
With the discovery in 1950 of transposable elements
(TEs) genomes began to seem far more dynamic than
hitherto conceived [1]. It is now clear that TEs have been
important long-term drivers of genome evolution. Year by
year, more and more ways in which mobile DNA impacts
gene expression and integrity, cell variability and viability,
and ultimately human health are revealed. With recent
discoveries that TEs are active not only in the germline
but also in somatic cells, it is evident that each of us is a
mosaic of different genomes that now seem dynamic in-
deed (reviewed by [2] and many others).
Retrotransposon TEs include long terminal repeat (LTR)
and non-LTR class elements. Both retrotranspose by a
“copy and paste” mechanism involving reverse transcription
of an RNA intermediate and insertion of its cDNA copy at
a new site in the genome. LTR-retrotransposons, including
human endogenous retroviruses (HERVs), are remnants of
past germ line infections by retroviruses that subsequently
lost their ability to reinfect cells. While the HERV-
K(HML-2) group includes some polymorphic proviral loci
[3, 4], human LTR retrotransposons generally are
insertionally inactive, although many remain capable of
transcription. Long Interspersed Element-1 (LINE-1, L1)
retrotransposons are the only active autonomous mobile
DNA in humans. Alone they occupy at least 17% of our
genome and have also been responsible for the insertion in
trans of thousands of processed pseudogenes and a million
non-autonomous Short Interspersed Elements (SINEs), in-
cluding Alu and SVA (composite SINE/VNTR/Alu) ele-
ments [5]. The 6.0 kilobase (kb) bicistronic human L1 has a
5' untranslated region (UTR) that functions as an internal
promoter, two open reading frames (ORF1 and ORF2), and
a 3' UTR. A weak promoter also exists on the antisense
strand of the human L1 5' UTR [6]. ORF2 encodes a
150-kilodalton (kD) protein with DNA endonuclease and
reverse transcriptase (RT) activities. While the 40 kD
ORF1p RNA-binding protein is essential for retrotransposi-
tion, its exact role in retrotransposition is unclear, although
it possesses RNA chaperone and packaging properties [7–
9]. The great majority of L1s in the genome are 5' truncated
and otherwise rearranged or mutated and so incapable of
autonomous transcription.
There are 145 fully intact L1s in the human genome of
which cell culture retrotransposition assays suggest
about 100 remain potentially mobile in any individual
diploid genome [10–12]. There are also hundreds of full
length L1s lacking intact ORFs but possibly capable of
generating protein [13, 14]. While L1 expression is nor-
mally suppressed by a host of cellular factors, the sup-
pression is relaxed in embryonic stem cells, the early
embryo, and some cancers (reviewed in [15, 16]).
Notably, retrotransposons are also active in some brain
cells [17]. Loss of piRNA pathway proteins correlates
with elevated retrotransposon expression in Drosophila
brain [18], although in mammals this pathway seems to
act primarily in the germ line to control retrotransposon
activity (see [19] for review). Early studies showed L1
retrotransposition in dividing neuronal progenitor cells
(NPCs), especially those of the hippocampus [20, 21],
and subsequently in non-dividing neurons [22, 23].
High-throughput sequencing of single neurons con-
firmed endogenous L1 retrotransposition in the human
brain, although frequency estimates differed significantly
(reviewed in [24–27]). Thus, it has been proposed that
L1 activity contributes to neuronal plasticity [28]. Ele-
vated L1 retrotransposition has also been reported for
several human neurological conditions, including ataxia
telangiectasia [29], Rett syndrome [30], autism [31],
schizophrenia [32, 33], and major depressive disorder
[34], as well as in neuronal cell lines or brains of patients
exposed to opioids [35–37], and in brains of a mouse
model of Huntington's disease [38] and hippocampi of
mice following novel exploration [39] or diminished ma-
ternal care [40]. However, some of these studies relied
solely on DNA amplification by quantitative (q)PCR or
digital droplet PCR to compare L1 insertion copy
differences between test and normal states, strategies
that may fail to distinguish between bona fide genomic
L1 insertions and contaminating extrachromosomal
L1-derived nucleic acids. Some studies may therefore
warrant additional verification (see also [41, 42] and
discussion).
Several studies have also drawn connections between
altered expression of LTR retrotransposons and amyo-
trophic lateral sclerosis (ALS). ALS is a fatal neurode-
generative disease involving loss of upper and lower
motor neurons and afflicts 2 in 100,000 people each
year. Death typically follows 2 to 3 years after onset and,
while about 90% of cases are sporadic, the rest have a
family history of the disease. There are no current means
to reverse the course of ALS, and treatment involves ef-
forts to slow progression of symptoms [43]. ALS has
overlapping clinical presentations with frontotemporal
lobar degeneration (FTLD) and its most common sub-
type frontotemporal dementia (FTD), a neurolgical con-
dition affecting the frontal and temporal lobes and
marked by cognitive and behavioral impairment. About
20% of ALS patients also exhibit FTLD, and ALS and
FTLD have been seen as part of a continuous disease
spectrum [44].
Increased reverse transcriptase activity from an un-
known source is detectable in sera and cerebrospinal
fluids of non-HIV-infected ALS patients [45–48]. Dou-
ville et al. [49] correlated this RT activity with elevated
expression of a few HERV-K(HML-2) loci and increased
amounts of pol gene transcripts and RT protein in cor-
tical neurons of some ALS patients. Hadlock et al. [50]
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noted elevated immune response to HERV-K(HML-2)
Gag protein in serum samples from ALS patients, and
recently it was shown that overexpression of the
HERV-K(HML-2) envelope protein causes motor neuron
toxicity and motor dysfunction in transgenic mice [51].
However, it cannot be excluded that some of the elevated
RT activity observed is also due to increased expression of
LINE-1 retrotransposons. It is reasonable to presume that
cellular changes that increase HERV-K(HML-2) expres-
sion in ALS patients may similarly activate other retro-
transposons. Indeed, a recent study reported global
increases in expression of selected families of both LTR
and non-LTR retrotransposons in ALS and FTLD patients
with a hexanucleotide expansion in the Chromosome 9
Open Reading Frame 72 (C9orf72) ALS gene but not in
sporadic ALS cases or controls [52].
The accumulation of neuronal RNA and protein ag-
gregates, including cytoplasmic stress granules (SGs), is
a pathogenic hallmark of a number of neurodegenerative
diseases. Pathological aggregation of RNA-binding pro-
teins has been implicated in ALS, FTLD, Alzheimer's
disease, spinocerebellar ataxia, Huntington’s disease, and
inclusion body myositis. In the case of ALS, there is in-
creasing evidence that abnormal RNA processing and
abnormal self-aggregation of proteins, leading to altered
RNA granule formation and malfunction of protein
pathways, contribute to motor neuron death [53]. A key
pathological feature of ALS is the presence of cytoplas-
mic inclusions in degenerating motor neurons and oligo-
dendrocytes. Inclusions are not restricted to the spinal
cord and motor cortex but are present in other brain re-
gions, such as the frontal and temporal cortices, hippo-
campus, and cerebellum, and are especially evident in
patients with accompanying FTD [54]. What triggers
protein aggregation and what it means for cell pathology
and progression of the disease remain unclear.
Aggregation of TAR DNA binding protein 43
(TDP-43, product of the TARDBP gene) is especially in-
teresting as a unifying pathological marker of both
FTLD and ALS. Mutations in TARDBP are involved in
about 4% of familial (fALS) and 1% of sporadic ALS
(sALS) cases. However, even lacking a mutation, TDP-43
protein, while typically nuclear in healthy cells, is cleaved
and hyperphosphorylated and accumulates in ubiquiti-
nated cytoplasmic inclusions in almost all ALS and al-
most half of FTLD patients (reviewed in [55]). TDP-43
protein aggregation pathology also characterizes other
neurodegenerative disorders, including Parkinson's [56],
Alzheimer's [57] and Huntington's [58] diseases, and in-
clusion body myopathies [59].
Several features of LINE-1-encoded ORF1p are remin-
iscent of neurodegeneration-associated proteins. ORF1p
is an ubiquitinated and phosphorylated RNA-binding
protein prone to forming cytoplasmic aggregates, including
SGs [60–63]. Therefore, it is conceivable therefore that
abnormal expression of ORF1p in neuronal cells might
aggravate formation of cytoplasmic aggregates and con-
tribute to disease pathology. Here we analyzed subcel-
lular localization and aggregation features of LINE-1
ORF1p and ways they may be analogous to or differ from
those of neurodegeneration-associated RNA-binding pro-
teins. We show that some ALS-associated RNA-binding
protein mutants closely associate with ORF1p in cytoplas-
mic RNA granules of tumor cell lines, and that increasing
the expression of some ALS proteins, including TDP-43,
inhibits L1 retrotransposition in a cell culture reporter
assay. We also considered the possibility that LINE-1
retrotransposon activity may be associated with ALS dis-
ease. Reverse transcription (RT)-qPCR) analyses failed to
detect significantly altered expression of non-LTR Alu or
L1 elements in sALS tissues. However, by reanalyzing
publicly available RNA-Seq datasets, one previously exam-
ined for TE levels [52] and one hitherto untested, we con-
firmed misregulation of selected TE subfamilies in
C9orf72 gene-related ALS samples. While so far the evi-
dence is not compelling for ALS, we believe the potential
for altered non-LTR retrotransposon expression playing a
role in neurodegenerative disorders is worthy of continued
investigation.
Results
A common LINE-1 polymorphism alters formation of
ORF1p cytoplasmic RNA granules
Early studies showed that endogenous ORF1p concen-
trates in cytoplasmic granules in cultured cells or fixed
tissues [60, 64]. Overexpression or cell stress causes
ORF1p to enter stress granules (Fig. 1F) [60, 61, 65, 66].
Here we used the monoclonal α-human α-4H1 ORF1
antibody (Millipore Sigma; [67]), which targets ORF1p
N-terminal amino acids (aa) 35 to 44, to examine ex-
pression of endogenous ORF1p in 2102Ep cells, an em-
bryonal germ cell teratocarcinoma line that has
unchanging human embryonal stem cell (hESC) charac-
teristics [68, 69]. By Western blotting, α-4H1-ORF1
detected a robust approximately 42 kD band of size
consistent with the ORF1p monomer, a much weaker
85 kD band that likely marks ORF1p dimers, and
sporadically a band of 65 kD of unknown identity
(Additional file 1: Figure S1A). Single, less intense 42
kD bands were seen in human embryonic kidney HEK
293T and neuroblastoma SH-SY5Y cells. SH-SY5Y is a
thrice-cloned sub-line of the bone marrow-derived neural
line SK-N-SH, which shows significantly less ORF1p sig-
nal. No endogenous ORF1p was detected in human cer-
vical adenocarcinoma HeLa cells (Additional file 1: Figure
S1A).
Confirming previous results [60], constitutive aggrega-
tion of ORF1p in the cytoplasm was detected in multiple
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cell lines by multiple α-ORF1p antibodies (Additional
file 1: Figure S1B-E). However, the pattern and degree of
granule formation by ORF1p can vary significantly with
cell type. In human neuroblastoma SH-SY5Y cells, for
example, ORF1p granules are rare in the main cytoplasm
but evident in neurite outgrowths (Additional file 1: Fig-
ure S1C). Notably, endogenous ORF1p cytoplasmic ag-
gregates differ from SGs in certain ways. In the absence
of external stress, in 2102Ep cells small ORF1p aggre-
gates are numerous but only faintly and rarely marked
by SG proteins such as cytotoxic granule associated
RNA binding protein (TIA1) and elongation initiation
factor 3 (eIF3η) (Fig. 1A, C). Furthermore, unlike SGs
[70], endogenous ORF1p granules do not obviously dis-
semble during cell mitosis (Fig. 1E). As previously re-
ported, when exposed to sodium arsenite, an inducer of
Fig. 1 Cytoplasmic localization of L1 ORF1 protein. Stress granule marker proteins TIA1 (a, b) and eIF3η (c, d) show minimal colocalization with
endogenous ORF1p in cytoplasmic granules (shown by arrows) of unstressed human embryonal carcinoma 2102Ep cells (a, c) but colocalize in
large stress granules of cells treated with Na-arsenite (0.5 mM for 1 hour) (b, d). Cell nuclei are stained with Hoechst. Size bars are 10 μm. e
ORF1p cytoplasmic granules retain integrity during cellular mitosis. Patient sera-derived α-ANA-N marks nucleoli [60]. Endogenous ORF1p is
mostly excluded from metaphase chromatin plates (arrow), as shown by Hoechst staining (see arrow). f Ectopically expressed EGFP-tagged
human ORF1p induces prominent cytoplasmic granules, but (g) deletion of its Q-N-rich region abolishes granule formation. h The ORF1p R159H
point mutation reduces cytoplasmic granule formation by 50%. Approximately 500 cells were examined. i The R159H mutation abolishes cell
culture LINE-1 retrotansposition. pc6-RPS-EGFP-ΔCMV wild-type or R159H mutant retrotransposition reporter constructs were transfected in HEK
293T cells and 5 days later the percentages of EGFP-positive cells were determined by flow cytometry. The construct 99-PUR-JM111-EGFP served
as a negative control for retrotransposition [84]. Each construct was tested in quadruplicate wells with results for one biological replicate shown
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oxidative stress, ORF1p redistributes to larger-sized ag-
gregates that now mostly colocalize with SG proteins
(Fig. 1B, D). Thus ORF1p aggregates form constitutively
but do not chronically induce a cellular stress state that
is marked by redistribution of SG proteins.
Previously, it was shown that overexpressed ORF2p
and L1 RNA also colocalize with ORF1p in cytoplasmic
aggregates [60, 61, 63, 71]. Interestingly, we noted [72],
and others confirmed [73], that ORF2p is visible in only
a minor percentage of ORF1p-positive cells when the
two proteins are coexpressed from an L1 construct. The
reason for this is unknown but may relate to an uncon-
ventional translation mechanism of LINE-1 ORF2 [74].
Unfortunately, although α-ORF2p antibodies exist [75–
79], they are not widely available or are ineffective in de-
tecting endogenous ORF2p, and so we did not examine
ORF2p localization in this study.
Many RNA-binding proteins that form SGs have in-
trinsically disordered prion-like domains rich in glutam-
ine and asparagine (Q-N) residues. Aggregation of
prion-like domain proteins is characteristic of various
neurodegenerative disorders including ALS (reviewed in
[80]). No prion-like domain is predicted in ORF1p using
the PrionW [81] or PLAAC [82, 83] algorithms. How-
ever, human (but not mouse) L1 ORF1p contains a
Q-N-rich internal region (36% Q or N between residues
179 and 205, numbering according to accession number
AF148856.1). Deletion of this region abolishes granule
formation (Fig. 1F, G), indicating it is critical for human
L1 ORF1p aggregation properties.
Previously, we and others [60, 61] showed that muta-
tions in the N-terminus leucine zipper domain or the
C-terminal domain double-point mutation R261/262A
(the so-called JM111 mutation that abrogates cell culture
retrotransposition; [84]) also alter ORF1p cytoplasmic
aggregation. We also reported that a non-conservative
mutation, R159G, inhibits ORF1p granule formation.
This residue was subsequently shown to be important
for RNA-binding and is within the RNP2 sequence of
the ORF1p RRM (RNA recognition motif ) [85]. In the
present study, to ascertain the prevalence of L1s in the
human genome with R159 polymorphisms, we queried
the L1Base2 database [13]. L1Base2 is subdivided into 3
categories: L1s with intact ORF1 and ORF2 (FLI-L1s),
L1s with intact ORF2 but disrupted ORF1 (ORF2-L1s),
and non-intact L1s >4500 nucleotides in length
(FLnI-L1s). Although the R159G variant was detected at
only very low frequency (0.47% of 6346 alignable
FLnI-L1 sequences), many other R159 polymorphisms
were found, with R159H being most common. In all, we
identified R159 changes to histidine, cysteine or proline
residues in 4.8% of FLI-L1s, 11.5% of ORF2-L1s, and
40.3% of FLnI-L1s (Additional file 1: Figure S2A).
Thus, sequence variation in the aggregation-control
R159 codon of human L1 ORF1p is common in en-
dogenous L1s.
We introduced the R159H change into ORF1-
EGFP-L1-RP, a construct with CMV promoter and
ORF1 C-terminally tagged with EGFP followed by intact
downstream L1 sequence, and as expected observed a
30% decline in the number of HEK 293T cells with
ORF1p cytoplasmic granules (Fig. 1H). We next tested
the effect of the R159H polymorphism in a cell culture
retrotransposition assay. In this assay, an enhanced
green fluorescent protein (EGFP) reporter gene reporter
cassette, interrupted by a backwards γ-globin intron, is
inserted in opposite transcriptional orientation into the
3' UTR of L1-RP (a highly active human L1 [86]). The
EGFP reporter gene can be expressed from its own pro-
moter only after the L1 is transcribed, the γ-globin in-
tron is removed by splicing, the L1-reporter cassette
hybrid transcript is reverse-transcribed, and its cDNA
inserted in the genome [84, 87]. The R159H mutation
abolished cell culture retrotransposition to levels similar
to that observed for an L1 containing the ORF1p JM111
mutation that cannot form a functional L1 ribonucleo-
protein (RNP) complex [88] (Fig. 1I).
Finally, we considered the possibility that the abun-
dance of R159 polymorphisms might be due to a CpG
dinucleotide methylation hotspot. Following genome bi-
sulfite conversion, PCR amplification, cloning of the
amplicons and Sanger sequencing, we queried the
methylation status of nine CpGs within a 436-nt stretch
(1169-1604) of ORF1 surrounding the R159 codon. Al-
though CpGs were methylated (16 to 64%), we observed
no preference for methylation at the ORF1 R159 codon
(Additional file 1: Figure S2B).
Thus, L1 ORF1 polymorphisms can alter not only ret-
rotransposition efficiency but also ORF1p aggregation
dynamics for a subset of L1s abundant in the human
genome.
LINE-1 ORF1 protein concentrates in nuclear aggregates
Previously we showed that both overexpressed and
endogenous L1 ORF1p are not only cytoplasmic but co-
localize with nucleoli of a subset of cells (Fig. 2A). Over-
expressed ORF2p also enters nucleoli [76]. Here we
report that exogenously expressed GFP-tagged human
ORF1p also strongly concentrates at the nuclear mem-
brane and forms small discrete perinucleolar foci in 5%
or fewer of human osteosarcoma U2OS or HEK 293T
cells. These cells show an attendant reduction in the size
and number of cytoplasmic granules (Fig. 2B,C). Con-
sistently, endogenous ORF1p nuclear foci are also seen
in a small fraction of 2102Ep cells (Fig. 2D); presence of
the foci in nuclei was confirmed by z-series confocal im-
aging. Recently, De Luca et al. [79] also showed in human
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melanoma cells both endogenous ORF1p and ORF2p in
nuclear puncta that partially colocalized.
Using the MS2-NLS-GFP detection protocol [89], we
previously reported that overexpressed Alu SINE RNA
forms small distinct nuclear foci that partially associate
with coiled (Cajal) body marker proteins [72]. Coiled
bodies are nuclear non-membrane RNP suborganelles
involved in the processing of non-coding RNAs and have
been linked with the rare motor neuron disease spinal
muscular atrophy (SMA) [90]. In our present experi-
ments, we show that in the minor percentage of HEK
293T cells that form ORF1p nuclear foci, these foci
closely colocalize with coexpressed MS2-tagged Alu
RNA (Fig. 2E, detected here by fluorescent in situ
hybridization (FISH)). Thus, ORF1 protein and Alu
RNA may directly interact in the nucleus. SVA SINE
RNA expressed from plasmid pcDNA SVASPTA1-MS2 is
mainly cytoplasmic but also forms nuclear foci [72].
Interestingly, these foci do not colocalize with
ORF1-EGFP foci, despite the fact that both Alu and SVA
RNAs depend upon L1 for their retrotransposition and
insert in the genome by a common mechanism (Fig. 2F).
As previously reported, L1 RNA failed to form nuclear
foci in our experiments [61, 72].
Certain neurodegenerative conditions, including myo-
tonic dystrophy, fragile X-associated tremor ataxia syn-
drome and spinocerebellar ataxias, are associated with
genes that undergo long simple repeat expansion
Fig. 2 Nuclear localization of L1 ORF1 protein. a Endogenous ORF1p detected in 2102Ep cells by the α-4H1-ORF1 antibody. ORF1p is mostly
cytoplasmic where it concentrates in granules and occasionally at the nuclear membrane. It is faintly seen in the nucleoplasm and concentrates in
nucleoli of a subset of cells. b, c Exogenously expressed EGFP-tagged ORF1p strongly concentrates at the nuclear membrane and in perinucleolar foci
of 5% or fewer human (b) U2OS or (c) HEK 293T cells with attendant reduction in size and number of cytoplasmic granules. Cotransfected mCherry-
PSP1 marks nuclei and is excluded from nucleoli. d Endogenous ORF1p detected by α-4H1-ORF1 also forms discrete nuclear foci in a minor
percentage of 2102Ep cells. Selected foci are enlarged in panels to the right. e Alu RNA, tagged with six MS2 coat protein recognition stem loops and
expressed from construct pBS 7SL Alu-MS2 (Ya5), was detected by FISH using a Cy3-tagged DNA probe to the MS2 stem loops. Alu RNA colocalizes
with nuclear foci marked by EGFP-tagged ORF1p in HEK 293T cells. f Nuclear foci of MS2 stem loop-tagged full-length SVA RNA detected by the Cy3-
MS2 DNA probe do not colocalize with foci marked by ORF1p-EGFP. g RNA having 31 tandem G4C2 repeats detected by FISH using a Cy3-conjugated
(C4G2)4 DNA probe induces intense intranuclear or cytoplasmic RNA aggregates that colocalize with ORF1p-EGFP in a minor percentage of HEK 293T
cells (nuclear granules are marked by small arrows and cytoplasmic granules by large arrows). Size bars are 10 μm
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mutations. RNAs transcribed from these mutant genes
accumulate in nuclear foci [91]. A pathogenic GGGCC
(G4C2) hexanucleotide expansion in intron 1 of the
C9orf72 gene is the most common mutation associated
with both ALS and FTD [92, 93] and is implicated in
Huntington's disease [94]. Mutant C9orf72 gene tran-
scripts form toxic RNA foci in affected neuronal cells
and are associated with the disease pathology [92, 95].
We transiently coexpressed in HEK 293T cells
ORF1p-EGFP together with C9orf72 RNA having 31 tan-
dem G4C2 repeats, the latter detected by RNA FISH
using a Cy3-conjugated (C4G2)4 probe [96]. As with Alu
SINE RNAs, ORF1p-EGFP granules directly overlapped
or juxtaposed with G4C231 RNA granules in nuclei and
cytoplasm of some cells (Fig. 2G).
Thus, being a promiscuous RNA-binding protein, it is
possible that L1 ORF1p is able to bind and sequester
many cellular RNAs in granules present in both the
cytoplasm and nucleus.
The control of LINE-1 ORF1p nuclear localization in
2102Ep cells
Several studies have reported that cell division facilitates
efficient retrotransposition, citing a failure of L1s to ret-
rotranspose in cultured primary and tumor cells blocked
at G0 phase but disagreeing on the extent of retrotran-
sposition loss in G1/S-arrested cells (reporting a 3-fold
to 10-fold decline; [97–99]). Mita et al. [100] recently re-
ported that cell culture retrotransposition occurs prefer-
entially in S-phase. On the other hand, we previously
showed significant retrotransposition in non-dividing
neuronal cells differentiated from hESCs [23], and simi-
lar data was earlier observed in transformed cell lines
[97]. Since ORF1 protein is essential for active retrotran-
sposition [84], we chose to examine two mechanisms
postulated to control ORF1p subcellular localization, cell
cycle and active nuclear export.
2102Ep cells are nullipotent, manifesting a stable
phenotype; indeed, they are used as a reference to
characterize newly derived hESC lines [69]. However, we
noticed considerable variation in the percentage of
2102Ep cells showing obvious nucleolar localization of
endogenous ORF1p when examining clusters of cells
across a single slide using immunofluorescence (IF) and
the α-4H1-ORF1 antibody (between 0.6% and 36% of
total cells randomly examined in three separate experi-
ments). Less densely clustered cells more frequently
showed ORF1p nucleolar concentration. Germline
tumor cells, including 2012Ep cells, are altered for cell
cycling by cell-to-cell contact inhibition or serum deple-
tion [101], and we therefore wondered if concentration
of ORF1p in the nucleus might relate to cell cycle status.
Accordingly, we seeded 2102Ep cells at low densities
and blocked G1/S phase transition using aphidicolin, an
inhibitor of DNA polymerase α, or hydroxyurea, which
inhibits ribonucleotide reductase causing a loss of de-
oxyribonucleotides [102, 103], and examined effects on
endogenous ORF1p nucleolar localization. Cell cycle
blockage was confirmed by propidium iodide staining
followed by flow cytometry (Fig. 3A). Blocking the cell
cycle at G1/S had no significant effect on the average
percentage of cells with endogenous ORF1p nucleolar
localization (Fig. 3B), or on nuclear-cytoplasmic levels
following cell fractionation and Western blotting (Fig.
3C). For both treated and non-treated 2102Ep cells,
Western blotting showed a major amount of endogenous
ORF1p in the nuclear fraction, in agreement with Soko-
lowski et al. [104] who reported nuclear fraction concen-
tration of plasmid-expressed ORF1p in human HeLa
and mouse NIH3T3 cells. However, it is likely that some
of the ORF1p we detect in the nuclear fraction is due to
copurification of insoluble ORF1p cytoplasmic aggre-
gates [105]. Significantly, however, the amounts of
ORF1p detected by Western blotting in both cytoplas-
mic and nuclear fractions remained unaltered by cell
cycle blockage.
We next stained untreated 2102Ep cells with anti-
bodies to chromatin licensing and DNA replication fac-
tor 1 (CDT1), a G1 phase nuclear protein lost after
initiation of S phase [106], or Geminin (GMNN), a pro-
tein expressed only in S/G2/M phases [107], and then
examined cells for L1 ORF1p nucleolar concentration.
Immunocytochemistry showed that both CDT1 and
Geminin marked 2102Ep cells with or without endogen-
ous ORF1p visible in nucleoli (Fig. 3D, E). However, a
majority of cells showing nucleolar ORF1p failed to stain
with CDT1, while the opposite was true for Geminin
(Fig. 3F). This suggests partial nucleolar exclusion of
ORF1p during G1 phase but without stringent cell cycle
control. Our results in part contradict a recently pub-
lished observation [100] that overexpressed LINE-1
ORF1p is nuclear in HeLa cells expressing CDT1 (G1
phase) and almost completely cytoplasmic in cells ex-
pressing Geminin (see Discussion).
Next, we considered if LINE-1 ORF1p shuttles be-
tween the nucleus and cytoplasm, as is the case with
TDP-43 and some other prion-domain RNA-binding
proteins associated with neurodegenerative diseases
[108]. Shuttling proteins often contain nuclear export
signals (NESs), consisting of a short stretch of hydro-
phobic leucine-rich residues [109]. We previously re-
ported that subcellular localization of overexpressed
GFP-tagged ORF1p in HEK 293T cells was unaltered by
leptomycin B (LMB), a chemical inhibitor of the
chromosomal region maintenance 1 (XPO1/CRM1) nu-
clear export pathway [76]. We now observed that treat-
ment of 2102Ep cells with 55 nM LMB for 18 hours also
had no obvious effect on endogenous ORF1p localization
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(Additional file 1: Figure S3A). On the other hand, con-
trols revealed that LMB efficiently inhibited cytoplasmic
export of endogenous cyclin B1, which contains an NES
responsive to CRM1 (Additional file 1: Figure S3B) [110],
as well as a GFP-tagged phosphorylation mimetic mutant
of MAPKAP kinase 2 (MK2-mut T205/317E) that remains
in the cytoplasm once exported from the nucleus (Add-
itional file 1: Figure S3C) [111].
Previously, we fused a suspected ORF1p leucine-rich
NES (aa 87-93, LKELMEL) and linker to the C-terminus
of EGFP. While a functional NES should cause EGFP,
which is normally both cytoplasmic and nuclear, to become
more cytoplasmic [112], we failed to observe increased con-
centration of EGFP-LKELMEL in the cytoplasm [76]. For
the present study, we used the NetNES 1.1 Server [113] to
predict a second NES site at the C-terminus of ORF1p
(ORF1 aa 313-321, LKELLKEAL). Fusing this sequence to
the N-terminus of EGFP also failed to alter distribution of
EGFP (Additional file 1: Figure S3D). Moreover, altering
the sequence to encode LKEAAAAAL in construct
ORF1-EGFP-L1-RP failed to visibly affect its ORF1p
localization (Additional file 1: Figure S3E).
In contrast to our results, Mita et al. [100] reported a
20 to 35% increase in nuclear retention of exogenous
ORF1p overexpressed in HeLa cells treated with LMB.
While we failed to detect NES sequences in ORF1p or
obvious sensitivity to the CRM1 export pathway, we
cannot exclude the possibility that LMB causes nuclear
Fig. 3 ORF1p nuclear localization in 2102Ep cells is not strictly influenced by cell cycle status. a Cell cycle arrest was induced for 22 hours with 10
μg/ml aphidicolin or 3 mM hydroxyurea and confirmed by propidium iodide staining and flow cytometry. The percentages of cells in G0/G1, S or
G2/M phases were determined using BD CELLQuest software (BD Biosciences). FL2-Area is plotted against cell counts. b Percentage of cells
having visible nucleolar localization when not treated (NT) or treated with aphidicolin to induce cell cycle arrest at G0/G1 phase. c Endogenous
ORF1p was detected by Western blotting in both nuclear and cytoplasmic cell fractions left untreated (NT) or treated with aphidicolin (APH) or
hydroyxurea (HU). Purities of nuclear and cytoplasmic fractions are shown using α-Lamin A/C and α-MEK1/2 antibodies, respectively. WCL: whole
cell lysate. d,e) Immunofluorescence of 2102Ep cells showing that cells both with or without nucleolar ORF1p localization can express CDT1 or
Geminin. f The percentages of untreated 2102Ep cells having visible ORF1p nucleolar localization that are marked (+) or unmarked (-) by α-CDT1
(red bars) or Geminin (green bars) staining. The data summarizes three replicate experiments with at least 400 cells scored for each experiment.
Statistical significance was calculated by Student’s t-test (** p<0.01; *** p<0.001)
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retention of minor amounts of endogenous ORF1p not
visibly obvious in our system. Also, despite previous re-
ports of attenuated cell culture retrotransposition fol-
lowing G1/S phase arrest, our results suggest this is not
due to failure of ORF1p RNPs to enter nuclei, at least in
2102Ep cells, which are known to accommodate cell cul-
ture retrotransposition [114]. Moreover, despite the pre-
vious suggestion that nuclear membrane breakdown is
required for nuclear entry of L1 ORF1p [100] this does
not appear to be the case for this cell line.
ALS-related protein mutants colocalize with ORF1p in
cytoplasmic granules
To date at least 25 genes have been linked to ALS [43,
53]. The first ALS gene discovered, superoxide dismut-
ase (SOD1) [115], is mutated in about 20% of familial
cases. C9orf72 is by far the most frequent gene account-
ing for about 35% of fALS, 25% of fFTD, and 6% of sALS
cases [92, 93, 116]. RNA-binding protein FUS (FUS) and
TARDBP mutations each account for about 4% of fALS
cases. Other ALS-associated genes, including alsin
(ALS2), angiogenin (ANG), heterogeneous nuclear ribo-
nucleoprotein A1 (HNRNPA1), optineurin (OPTN),
sequestosome-1 (SQSTM1/P62), ubiquilin 2 (UBQLN2),
TANK binding kinase 1 (TBK1), valosin-containing pro-
tein (VCP) and VAMP-associated protein B and C
(VAPB) among others, account for only a small percent-
age of cases so confounding treatment strategies. ALS
animal models of neurodegeneration have mostly exam-
ined the toxic effects of overexpressing disease-related
aggregation-prone proteins. Mutants of several ALS-
associated RNA-binding proteins are known to shift
localization from the nucleus to the cytoplasm and form
RNA foci in the disease state [117, 118].
Previously, in a yeast two-hybrid screen we identified
FUS protein as an ORF1p interaction partner, and we
confirmed that the two wild-type proteins colocalized in
cytoplasmic granules of a minor percentage of stressed
human nTERA-2 embryonal carcinoma cells [60]. Here
we generated in-house or obtained from other sources
tagged constructs for selected ALS disease-associated
mutants and transfected these in HEK 293T or 2102Ep
cells in the presence of EGFP-tagged ORF1p or en-
dogenous ORF1p alone. Various ALS-associated mutant
but not wild-type FUS, TDP-43, and SOD1 proteins
strongly colocalized with ORF1p in granules of un-
stressed cells (Fig. 4A-C). When cellular oxidative stress
was induced by application of sodium arsenite, endogen-
ous TDP-43 formed numerous cytoplasmic granules that
strongly colocalized with endogenous ORF1p in most
cells (Fig. 4D). Wild-type TDP-43 is known to form SGs
in ALS neurons in response to cellular stress [119–121].
HNRNPA1 and HNRNPA2B1 are prion domain pro-
teins that bind TDP-43 and have been linked with some
ALS cases [122, 123]. Both proteins bind the L1 RNP,
and HNRNPA1 colocalizes with ORF1 in SGs, as previ-
ously reported ([60, 124]; Fig. 4E). Wild-type TIA1, re-
cently found mutated in cases of ALS and FTD [125],
also strongly colocalizes with ORF1p in stressed cells as
noted above (Fig. 1B). However, some ALS-related pro-
teins, including OPTN and ANG (Fig. 4F, G), fail to co-
localize in the same granules with ORF1p.
Expanded hexanucleotide repeats within transcripts of
the C9orf72 ALS gene can undergo non-conventional
repeat-associated non-ATG (RAN) translation and gen-
erate dipeptide repeats that form inclusions in cerebel-
lum, neocortex, and hippocampal neurons of C9
patients and toxic cytoplasmic aggregates in cultured
neuronal cells or Drosophila models ([126–129],
reviewed in [130]). To determine if these aggregates also
colocalize with those of L1 ORF1p, we coexpressed in
cultured cells a C9orf72 RAN translation product con-
sisting of 50 GA repeats tagged with EGFP [131] and full
length L1 with FLAG-HA-tagged ORF1. However, while
overexpressed dipeptide proteins formed one to three
large cytoplasmic aggregates in each cell, these did not
colocalize with and generally excluded ORF1p (Fig. 4H).
Thus, a subset of RNA-binding proteins mutated in
ALS bind and colocalize with L1 ORF1p RNP in cyto-
plasmic RNA granules.
Overexpression of some ALS-associated proteins inhibit
cell culture retrotransposition
We previously showed that retrotransposition occurs in
non-dividing mature neurons [23]. Here we extended
these analyses and tested retrotransposition in two cell
lines often used to study neurodegeneration, human
SH-SY5Y neuroblastoma and mouse NSC-34 neuronal
cells, the latter a hybrid line generated by fusing spinal
cord motor neurons with neuroblastoma cells (Fig. 5A).
Due to inefficient plasmid transfection, we infected cells
with the adenovirus-retrotransposon hybrid virus, A/
RT-pgk-L1RP-EGFP (Ad-L1) [23, 97]. This viral con-
struct contains L1-RP tagged with the EGFP retrotran-
sposition reporter cassette. Retrotransposition detected
by flow cytometry was 1.1% and 0.6% of gated SH-SY5Y
and NSC-34 cells, respectively. Thus, both primary and
transformed neuronal cell lines are competent for
retrotransposition.
We next asked if ALS-related proteins alter L1 retro-
transposition in the cell culture assay described above
[84, 87]. Briefly, we transfected HEK 293T cells with the
retrotransposition reporter construct 99-PUR-RPS-EGFP
together with constructs expressing tagged ALS-related
proteins. 99-PUR-RPS-EGFP includes full-length L1-RP
with the EGFP reporter cassette in its 3' UTR cloned in
a modified version of pCEP4 vector (Invitrogen) lacking
a cytomegalovirus (CMV) promoter. All constructs were
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expressed in HEK 293T cells (Fig. 5B, top). At least 3
biological replicates were performed. Test proteins did
not cause significant cell death during the course of the
experiment as determined by trypan blue exclusion
staining (Additional file 1: Figure S4A). Three out of 14
proteins tested, including SQSTM1, TDP-43, and TBK1
kinase, reduced cell culture retrotransposition 50% or
more when compared with cells transfected with empty
vector only as control (Fig. 5B, bottom). SQSTM1/P62 is
an autophagy receptor that targets bound proteins for
selective degradation. Autophagy has previously been
linked with retrotransposon restriction, and it was
shown that SQSTM1 colocalizes with L1 RNA in stress
granules, and that its knockdown causes increased
accumulation of L1 and Alu RNAs and genomic inser-
tions in cultured cells [71]. Autophagy misregulation has
also been linked with numerous neurodegenerative dis-
orders, including ALS.
TDP-43 is a multifunctional RNA-binding protein with
roles in mRNA transcription, translation, transport, spli-
cing, and stability [132–134]. Studies in model organ-
isms have shown that overexpression of wild-type
TDP-43 mimics loss-of-function phenotypes of neurode-
generation and motor dysfunction [135, 136]. Several
other studies have considered how endogenous TDP-43
levels affect expression of TEs but with inconsistent results
([49, 51, 52, 137–139]; see discussion). In the HEK 293T
cell culture retrotransposition assay, ectopic expression of
Fig. 4 ALS-associated protein mutants colocalize with ORF1p in cytoplasmic aggregates of HEK 293T and 2102Ep cells. a Exogenously expressed
wild-type 3XFLAG-tagged FUS protein is nuclear and only rarely colocalizes with ORF1-EGFP in the cytoplasm, but some mutants strongly overlap
in cytoplasmic granules of unstressed HEK 293T cells. b GFP-tagged wild-type TDP-43 is mostly nuclear with only faint colocalization with
endogenous ORF1p in cytoplasic foci of some unstressed cells (arrows, top panels). However, mutations to the TDP-43 NLS (K82/84A and A90V)
and some ALS-associated mutations (for example, A315T) show colocalization with ORF1p in cytoplasmic granules. c Cherry tomato-tagged wild-
type SOD1 protein is diffusely cytoplasmic (top), but some ALS mutants are present with ORF1p in cytoplasmic foci of 293T cells. d Endogenous
TDP-43 strongly colocalizes with endogenous ORF1p in cytoplasmic granules of Na-arsenite stressed but not untreated 2102Ep cells. ORF1p foci
are much increased in size in stressed cells. e Red fluorescent protein (RFP)-tagged hnRNPA1 colocalizes with ORF1-EGFP cytoplasmic granules in
unstressed HEK 293T cells. f, g Cytoplasmic granules formed by exogenously expressed OPTN or ANG do not colocalize with ORF1-EGFP granules.
h) ORF1p is generally excluded from GFP-(GA)31 dipeptide aggregates. The full-length L1 construct pc-L1-1FH expresses ORF1p with HA-FLAG
tags. Size bars are 10 μm
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TDP-43 with an N-terminal Myc-tag inhibits L1 retrotran-
sposition over 90% (Fig. 5B). As this was the ALS-related
gene that most altered retrotransposition levels, we next
sought to characterize TDP-43 effect on L1 activity in more
detail. To determine if ORF1p and TDP-43 interact, we
co-expressed a construct containing L1-RP with T7-tagged
ORF1 (ORF1-T7-L1RP) and TDP-43 with a C-terminal
FLAG-tag: the two proteins co-immunoprecipitated
on α-FLAG agarose (Fig. 5C). This association was
RNA-dependent and was lost upon treatment with
RNase, similar to almost all other proteins previously
identified within the L1 ORF1p RNP [73, 124, 140, 141].
Over-expression of TDP-43 is toxic to neurons and
cell toxicity has been associated with increased cytoplas-
mic mislocalization of some TDP-43 mutant proteins
[142, 143]. We therefore thoroughly tested for
TDP-43-induced toxicity of HeLa or HEK 293T cells by





Fig. 5 Increasing expression of some ALS-associated proteins alters retrotransposition in cell culture assays. n=number of biological replicates. a
L1-RP is retrotransposition-competent in human SH-SY5Y neuroblastoma and mouse NSC-34 motor neuron-like cells. Cells in 6-well plates were
infected with A/RT-pgk-L1RP-EGFP (Ad-L1) L1-reporter adenovirus [97] at about 8 × 1012 viral particles/ml. Flow cytometry analysis was performed
at 9 days post-infection. b 99-PUR-RPS-EGFP was co-transfected in HEK 293T cells with empty vector (pcDNA3) or test constructs expressing
tagged ALS-related proteins. Five days later, percentages of EGFP-positive cells were determined by flow cytometry. Each plasmid pair was
transfected in four replicate wells, with at least 3 replicate experiments performed for each construct. Results are normalized to pcDNA3 vector
control (lighter bar). Statistical significances compared with vector control were calculated by Student’s t-test (* p<0.05; ** p<0.01; *** p<0.001).
All test proteins were expressed as confirmed by Western blotting of whole cell lysates using α-DYKDDDDK (FLAG)-tag, α-Myc-tag, or α-V5-tag
antibodies as indicated (top). Four-fold less V5-SQSTM1- and three-fold more V5-TBK1-transfected lysates were loaded on the gel. Full-length TBK1
expressed poorly, most of the protein existing as a high molecular weight smear. c FLAG-tagged TDP-43 co-immunoprecipitates T7-tagged L1
ORF1p complexes from HEK 293T cell lysates after α-FLAG-M2 affinity gel purification. Interaction is lost following treatment of lysates with RNase.
d Expression of V5- or Myc-tagged TDP-43 strongly inhibits mouse IAP element retrotransposition in HeLa-JVM cell culture. Cells were treated
with neomycin (G418) to select for retrotransposition events. Colony counts are not normalized. On the right are representative T75 flask images
with Giemsa-stained IAP retrotransposition-positive colonies in the absence or presence of TDP-43. The apparent diminished effect on
retrotransposition of Myc-TDP-43 compared with TDP-43-V5-WT is likely because its plasmid backbone does not replicate and is diluted out of
cells during the course of antibiotic selection which spans a couple of weeks
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overexpression on constitutive expression of antibiotic
resistance in HeLa cells (Additional file 1: Figure S4B,
C), 2) trypan blue staining for cell viability in HEK 293T
cells (Additional file 1: Figure S4D), and 3) MultiTox-
Fluor Multiplex Cytotoxicity Assay kit (Promega) analysis
in HEK 293T cells (Additional file 1: Figure S4E).
Overexpression of TDP-43 had no significant effect on cell
viability during the time course of our assays, indicating the
drop in retrotransposition efficiency is not a reflection of
cellular toxicity.
We next tested if overexpression of TDP-43 might also
inhibit the mobilization of LTR TEs. Human endogenous
retroviruses are thought to be incapable of replication
due to the presence of inactivating mutations in their
ORFs [4]. However, mouse intracisternal A particle
(IAP) LTR retrotransposons actively replicate and cause
new mutations by insertional mutagenesis. Using an
established cell culture assay [144], we found that in
HeLa cells overexpression of C-terminal V5- or
N-terminal Myc-tagged TDP-43 strongly restricted ret-
rotransposition of an IAP element tagged with a neomy-
cin phosphotransferase reporter cassette (Fig. 5D).
In a reciprocal assay, we next asked whether loss of
endogenous TDP-43 affects L1 cell culture retrotranspo-
sition. We confirmed by Western blotting that two dif-
ferent siRNAs efficiently repressed endogenous TDP-43
protein when transfected in HEK 293T cells. However,
TDP-43 depletion had no obvious effect on L1 retrotran-
sposition, at least using the EGFP-based retrotransposi-
tion assay (Additional file 1: Figure S5A). We note that
an inherent limitation of these assays is the transient na-
ture of the siRNA-mediated protein depletion.
We also wondered if TDP-43 expression might affect
the methylation status of the CpG island within the L1
5' UTR promoter [145]. We performed bisulfite conver-
sion of genomic DNA from HEK 293T cells in which
TDP-43 was either overexpressed (1 experiment;
Additional file 1: Figure S6A) or depleted (2 inde-
pendent experiments; Additional file 1: Figure S6B, C).
PCR-amplified fragments containing the CpG island were
cloned and at least 15 amplicons were sequenced for each
sample [146]. Unexpectedly, when compared with con-
trols, the 17 CpG residues of this region showed a signifi-
cant overall increase in methylation in all experiments,
although fully unmethylated sequences were found in all
conditions. Therefore, one might speculate that perturb-
ing steady-state TDP-43 protein levels alters DNA methy-
lation status, a function for TDP-43 not to our knowledge
previously reported. However, changes in L1 promoter
methylation associated with TDP-43 expression were not
accompanied by significant change in activity of either the
L1 sense or antisense promoter in luciferase assays, at
least using a plasmid-based assay (Additional file 1: Figure
S6D). Moreover, TDP-43 overexpression failed to alter
levels of endogenous or ectopically expressed ORF1p
in cell culture, as determined by Western blotting
(Additional file 1: Figure S5B, C), nor consistently affected
levels of endogenous L1 RNA in HEK 293T cells as de-
tected by RT-PCR (Additional file 1: Figure S5D).
To complement these analyses, we next re-analyzed
two available RNA-Seq datasets not previously examined
for TE expression (Fig. 6A, B). The first study (SRA
SRP057819) generated single-replicate paired-end 100-bp
RNA-Seq data of control and TDP-43-depleted HeLa
cells (using the same esiTARDBP siRNA shown in
Additional file 1: Figure S5A) [147]. The second dataset
(GEO GSE77702) includes single-end 50-bp RNA-Seq
data (two replicates each) of wild-type human
iPSC-derived motor neurons depleted by shRNAs of
TDP-43, TAF15, FUS, or combined TAF15-FUS [148].
FUS and TAF15 are both members of the FET family of
RNA-binding proteins, which are linked with several
neurodegenerative disorders [149]. In the HEK 293T
cell culture retrotransposition assay, overexpressing
FUS had no effect, while TAF15 reduced retrotransposi-
tion by 38% (Fig. 5B).
To detect changes in TE expression, we plotted RPKM
(Reads Per Kilobase of transcripts per Million mapped
reads) values for a subset of mostly evolutionarily young
primate-specific non-LTR retrotransposons, including L1,
Alu and SVA, and LTR5_Hs (HERV-K(HML-2)) and
LTR7Y (HERV-H) subfamilies. Study SRP057819 showed
an increase (approximately 15%) in RPKM values for the
TDP-43 knockdown (KD) versus control HeLa cell lines
for L1s only (including L1PA2 and human-specific L1-Ta
and L1-pre-Ta subfamilies) (Fig. 6A, left). However, there
was a slight overall decrease in the percentage of retro-
transposon (LINE, SINE, SVA, and LTR)-related RNA-Seq
reads among the total number of mappable (gene and TE)
reads in TDP-43 KD cells (Fig. 6A, right). For
TDP-43-depleted motor neurons of study GSE77702,
there was a modest but consistent increase in RPKM
values for all retrotransposon subfamilies when compared
with scrambled shRNA control (Fig. 6B, left). In addition,
there was a modest increase from 7.6 to 9.8% in the per-
centage of retrotransposon RNA-Seq reads among total
mapped reads (TEs and genes) for TDP-43 KD versus
control motor neurons (Fig. 6B, right). A scatter plot,
however, showed minimal change in the expression profile
of all mapped TE subfamilies versus genes for the
GSE77702 dataset (Fig. 6B, bottom).
We then analyzed the GSE77702 dataset with TEtran-
scripts [150], a software package that uses short-read
alignment files to identify differentially expressed (DE) TE
subfamilies listed in RepBase, a database of representative
repeat sequences in eukaryote genomes [151, 152]. A total
of 192 retrotransposon subfamilies were expressed at sig-
nificantly different levels in TDP-43 KD cells at an adjusted
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P-value (padj) <0.05 (Additional file 2: Table S1). However,
only 55 retrotransposon TEs were significantly DE in the
TDP-43 KD but in neither the TAF15 nor FUS KD datasets.
Notably, only three DE retrotransposon TEs (HERVK3-int,
MamGyp-int, and MER51D) were unique to TDP-43 KD
cells and absent in the TAF15, FUS, and combined
TAF15-FUS KD groups.
Therefore, and in contrast to some reports (see discus-
sion), our analyses do not indicate a clear TDP-43-specific
link with elevated activity of TEs, particularly LINE-1
retrotransposons. In fact, overexpression of wild-type
TDP-43 strongly inhibits cell culture retrotransposition of
both human L1 and mouse IAP elements.
Mutation of some ALS-associated proteins alters cell
culture retrotransposition
TDP-43 contains a NLS and NES, two RNA-recognition
motifs (RRM1 and RRM2) that bind nucleic acids, and a
C-terminal glycine-rich region that mediates protein in-
teractions (Fig. 6C, top) [133]. A review in 2009 identi-
fied 70 pathogenic mutations in TDP-43, a majority in
the glycine-rich domain [153]. We wished to determine
if ALS-associated TDP-43 mutations might restore in-
hibition of retrotransposition by the wild-type protein,
and so we tested the effects on L1 cell culture retrotran-
sposition of a subset of mutant constructs. While all





Fig. 6 Effects of wild-type and mutant ALS-associated proteins on retrotransposon activity. a Plots of RPKM values for selected primate-specific non-LTR L1,
Alu and SVA or LTR5_Hs (HERV-K(HML-2)) and LTR7Y (HERV-H) retrotransposon subfamilies in RNA-Seq data of control and TDP-43-depleted HeLa cells of
study SRP057819 [147] (left). The percentage of reads originating from retrotransposons among total mapped reads (TEs and genes; right). b Plots of RPKM
values for selected primate-specific retrotransposon subfamilies for human iPSC-derived motor neurons depleted or not depleted of TDP-43 by shRNA
targeting from study GSE77702 [148]. Two replicate libraries were generated and sequenced in the GSE77702 dataset (left). The percentage of
retrotransposon-related reads among total mappable reads (right). Scatter plot of the expression profiles of all genes (blue) and retrotransposon TEs (red)
for the TDP-43 knockdown versus control motor neuron samples of GSE77702 (bottom). c Mutations within the nuclear localization signal (NLS) and RRM2
domains partially rescue inhibition of cell culture L1 retrotransposition by wild-type V5-tagged TDP-43. Top: the domain structure of TDP-43 showing the
location of point mutations tested. NTD: N-terminal domain. n=number of biological replicates. d The ALS-associated ANG mutation H37R, but not H138R,
significantly rescues cell culture L1 retrotransposition inhibition caused by expression of wild-type V5-ANG. e ALS-associated point mutations within the
NLS of FLAG-tagged FUS significantly reduce cell culture retrotransposition compared with the wild-type protein. Statistical significance was calculated by
Student’s t-test (*, p<0.05; **, p<0.01; ***, p<0.001)
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most mutations had no significant effect (Fig. 6C,
bottom). However, a non-ALS TDP-43 double-point
mutation in the N-terminal bipartite NLS (K82/84A)
restored retrotransposition 3.5-fold (p<0.001). Similarly,
ALS-associated NLS domain mutation A90V and RRM2
domain mutation K263E [154, 155] each rescued retro-
transposition 2-fold (p<0.05).
We also considered the effect of angiogenin mutations
on cell culture L1 retrotransposition. ANG is a member of
the pancreatic RNase A superfamily and a potent medi-
ator of neovascularization, as well as being a host defense
factor against some microorganisms [156] and an enhan-
cer of motor neuron survival [157, 158]. To date 33 ANG
mutations have been implicated in ALS and Parkinson's
disease [159]. Overexpression of V5-tagged ANG protein
reduced cell culture retrotransposition to 62% of empty
vector control without obvious cytotoxicity (Fig. 5B, 6D,
S4C). We then introduced two disease-associated muta-
tions known to abolish ANG RNase activity [159–161].
Notably, mutation H138R (H114R in the mature protein
after signal peptide cleavage) had no effect, while H37R
(H13R) restored retrotransposition to 87% when com-
pared with vector-only control (Fig. 6D).
Similarly, we examined the effect of mutations in FUS
protein. Exogenous expression of wild-type FUS had no
effect on cell culture retrotransposition nor obvious cyto-
toxicity, but ALS-related mutations in its C-terminal NLS
(R514G and H517Q) inhibited retrotransposition over
20% (Fig. 5B, 6E S4D, E). Finally we tested the effect of
mutations in TBK1 on L1 retrotransposition. TBK1 is a
member of the IKB kinase family, and an important player
in innate immune signaling. Mutations in TBK1 also im-
pair autophagy (153). Two mutants of TBK1, the
kinase-dead mutant S172A and the ALS-associated mu-
tant E696K (152) were tested, but neither showed any
change from the 50% reduction of cell culture L1 retro-
transposition caused by overexpression of the wild-type
protein (Additional file 1: Figure S4F).
In sum, increased expression of some neurode
generation-related proteins may decrease retrotransposon
activity, while some disease-related mutations can modify
these effects.
Retrotransposon expression in tissues of ALS patients and
controls
To further determine if changes in expression of
non-LTR class retrotransposons are associated with
ALS, we performed RT-qPCR analyses of 108 bulk spinal
cord and brain tissue samples of 38 ALS patients and 27
non-affected controls (Additional file 3: Table S2) ac-
cording to methods described in [146]. We assayed 30
thoracic or cervical spinal cord samples (15 ALS, 15
controls), 16 cerebellum (9 ALS, 7 controls), 35 motor
cortex samples (23 ALS, 12 controls), 19 occipital cortex
samples (14 ALS, 5 controls), and 8 hippocampal sam-
ples, all of the latter from ALS patients. Most samples
were from sALS patients or patients of unknown eti-
ology; only 5 patients had a known gene mutation.
RT-qPCR primer pairs targeted the ORF1 and ORF2
regions of the young human-specific and retrotranspo-
sitionally active L1Hs subfamily (Additional file 1: Figure
S7A, B) and two Alu subfamilies, AluS and AluY
(Additional file 1: Figure S7C, D). Younger than AluJ ele-
ments, the AluS subfamily arose about 40 million years
ago and may include some retrotransposition-competent
elements [162, 163]. AluY, the youngest lineage, has the
most retrotranspositionally active elements, and many
genetic disorders in humans have been generated by AluY
insertions [162, 164, 165]. Only L1Hs (L1P1)-type L1s are
known to be retrotransposition-competent in the human
genome [12, 166]. For the purposes of comparison, tran-
script levels were also determined for H9-hESCs [167]),
human embryonic fibroblasts (HEFs), and HeLa cells.
Transcript levels were determined in duplicate for
each brain and spinal cord sample, normalized to
GAPDH internal control, and averaged. We considered
all measurements of sample-specific transcript levels as
real and did not omit possible outliers from analyses.
Averaged RT-qPCR reactions within each experiment
were normalized to expression of H9-hESCs as these
cells strongly express endogenous L1 RNAs [168]; means
and standard deviations are shown in Additional file 1:
Figure S7. As previously observed, H9-hESCs expressed
5 to 25 times more L1 RNA than differentiated cultured
cells such as HEFs or HeLa [146]. Expression levels of
Alu and L1 element-related sequences detected in tissue
samples were as high or higher than in H9 cells. Average
expression in cerebellum was 2- to >3-fold higher than
in other tissues for both Alu subfamilies and for L1s (ex-
cept for ORF1 in occipital cortex); however, transcript
levels in cerebellum and for L1 ORF1 in all brain tissue
regions varied considerably between samples. Comparing
expression of Alu and L1 elements in ALS versus un-
affected controls, only expression of AluS elements in
occipital cortex was significantly elevated for the 14 ALS
versus 5 control samples (p=0.02) (Additional file 1:
Figure S7C).
We next examined ORF1p expression by Western
blotting of 60 brain and spinal cord tissue lysates
(Additional file 1: Figure S8, Additional file 3: Table S2).
There are very few studies of endogenous L1 protein ex-
pression in the brain. Baudin de The et al. [22] detected
L1 ORF1p in ventral mid-brain tissues of mouse. Using a
commercial antibody, Moszcynska et al. [169] showed by
immunocytochemistry putative ORF2p expression in sev-
eral rat brain regions, although antibody specificity was
not assessed. Sur et al. [170] detected ORF1p by immuno-
histochemistry of various brain regions, and antibody
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detection by Western blotting was confirmed for a single
frontal cortex sample. Here, using Western blotting and
the α-4H1-ORF1 antibody, we were, surprisingly, unable
to detect an ORF1p band of appropriate size in frontal
cortex, cerebellum, or hippocampal brain tissue samples,
and only very faintly in some motor cortex samples, even
when 50 μg of whole cell lysate was loaded in a well
(Additional file 1: Figure S8A-D) and despite the de-
tection of L1-related RNAs expressed in these tissue
types by RT-qPCR (Additional file 1: Figure S7). In
contrast, we could detect a very robust full-length
ORF1p signal from an equal amount of 2102Ep cell
protein lysate (Additional file 1: Figure S8). Distinct
bands consistent in size with full-length ORF1p were
observed in some spinal cord samples; bands of
smaller size were also seen, including a robust 38 kD
signal of unknown origin (Additional file 1: Figure
S8E). However, no overall differences in expression of
ORF1p were evident in ALS compared with control
spinal cord samples. Testing two different antibodies
showed that failure to detect ORF1p signal in the
brain was not limited to the α-4H1-ORF1 antibody
(Additional file 1: Figure S8F, G).
In general, interpretation of TE expression from
RT-qPCR data may be influenced by the presence of
exonized TE-derived sequences in genes, the possible
presence in the cell of non-integrated TE-derived
cDNAs (see discussion below), and the cellular hetero-
geneity of the tissues analyzed. TE activation may occur
in only a subset of cells within bulk tissue samples, so
limiting sensitivity of detection, and in the case of motor
neurons these cells may be progressively eliminated in
the disease state. In sum, however, no major differences
in TE expression where detected in ALS patients when
compared with controls.
Retrotransposon expression in ALS RNA-Seq datasets
Prudencio et al [171] generated a paired-end total
RNA-Seq data set (GSE67196) from cerebellum and
frontal cortex samples of 9 healthy, 8 C9orf72-associated
ALS (C9ALS), and 10 sALS individuals and analyzed
these for differentially expressed genes. A subsequent re-
analysis of the same datasets using the HOMER analy-
zeRepeats program revealed significantly increased
global expression of repetitive element types in frontal
cortex but not cerebellum of C9ALS compared with
sALS patients and healthy controls [52]. Setting
FDR<0.1, the authors reported 300 DE TE subfamilies in
the C9ALS samples: LTR class elements predominated
(46%), followed by DNA elements (19%) and LINEs
(18%). Notably, 91% of significant C9ALS DE repetitive
elements had increased expression.
We sought to assess further the degree to which TEs
are differentially expressed in sALS-associated tissues by
using TEtranscripts [150] to analyze two RNA-Seq data-
sets, SRP064478 and GSE76220, both publicly available
in sequence read archives and neither previously exam-
ined for repeat expression (see also the Methods
section). SRP064478 includes paired-end 150-bp se-
quence derived from total RNA of 7 sALS and 8 healthy
control post-mortem cervical spinal cord samples. No
significant difference in the percentage of averaged
retrotransposon-derived reads among the total number
of mappable reads (TEs and genes) was detected for
ALS vs control samples; 1.72 to 3.41 million sample
reads mapped to retrotransposon subfamilies (Fig. 7A,
left; Additional file 2: Table S1). Only one significant DE
retrotransposon subfamily was detected for SRP064478
(padj<0.05; Additional file 2: Table S1). However, overall
mapping efficiency was low: about 25 million reads were
alignable to the genome and 30% of these mapped to
mitochondrial genes.
The GSE76220 dataset consists of single-end 50-bp se-
quence of total RNA isolated from laser-capture micro-
dissected lumbar spinal cord sections of 13 sALS
patients and 8 control individuals [172]. There was no
significant change in the percentage of retrotransposon
reads among total mappable reads in the sALS vs con-
trol samples (Fig. 7A, right; Additional file 2: Table S1).
Between 0.27 and 1.26 million sample reads mapped to
retrotransposons. TEtranscripts detected only four sig-
nificant DE retrotransposon subfamilies (Additional file 2:
Table S1).
We then reanalyzed the GSE67196 RNA-Seq dataset
of Prudencio et al. [52, 171] using TEtranscripts. Signifi-
cant increases in retrotransposon reads as a percentage
of total mapped reads were seen for frontal cortex
C9ALS vs control (p=0.04) and C9ALS vs sALS (p=0.01)
samples (between 0.24 and 0.61 million sample reads
mapped to retrotransposons) (Fig. 7B). As expected,
multidimensional scaling (MDS) plots showed weak
clustering of C9ALS samples in frontal cortex but not
cerebellum samples (Fig. 7C). TEtranscripts detected no
significant DE TEs in cerebellum samples of the
GSE67196 dataset (padj<0.05). In the case of the frontal
cortex samples however, and supporting Prudencio et al.
[52], there were 3 DE TEs (DNAs, LTRs, LINEs, SINEs,
and SVAs) in sALS vs controls, 10 DE TEs in C9ALS vs
controls, and 133 DE TE subfamilies in C9ALS vs sALS
samples, all increased in expression and including 36%
LTR, 32% DNA, 15% LINE, and 17% SINE elements
(Additional file 2: Table S1).
We also analyzed for the first time TE expression for
the NeuroLINCS dbGaP Study phs001231 (SRP098831).
This dataset consists of poly(A)+ non-stranded mRNA
of iPSC-derived motor neurons from 4 C9ALS and 3
SMA patients (3 sequencing replicates each) and 3 un-
affected controls (2 or 3 replicates each). Transcripts of
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some TE types are not polyadenylated and so are likely
underrepresented in this dataset following poly(A)+ se-
lection. However, although Alu elements are transcribed
by RNA polymerase III and not polyadenylated, they
contain both internal and 3'-end poly(A) stretches guar-
anteeing capture of their transcripts. An MDS plot
showed C9ALS samples clustered away from SMA and
control samples, while clustering of SMA from control
samples was less evident (Fig. 7D, left). There was a sig-
nificant increase (p=0.02) in the percentage of retro-
transposon reads among total mappable reads in the
C9ALS vs control dataset (Fig. 7D, right). The increase
was also significant for C9ALS vs SMA (p=0.002) but
not significant for SMA vs control samples (p=0.46) (not
shown). TEtranscripts analysis showed that at padj<0.05,
significant DE TE subfamilies (DNAs, LTRs, LINEs,
SINEs, and SVAs) numbered 536 for C9ALS vs controls,
232 for C9ALS vs SMA, and 304 for SMA vs controls,
most TEs being increased in expression (Additional file
2: Table S1). Three SVA and 30 Alu TEs were upregu-
lated for C9ALS vs controls, including 6 AluY subfam-
ilies. (The human-specific L1Hs/L1P1 subfamily was not
detected). Interestingly, a recent literature review noted
at least 37 neurological and neurodegenerative disorders
linked with misregulated Alu retrotransposon activity
[173]. A caveat of this dataset analysis is that sample
numbers were small.
Algorithms such as Homer and TEtranscripts map se-
quencing reads to TE consensus sequences only and
locus-specific information is lost. The ability to map in-
dividual transcribed retrotransposons to their source loci
can reveal (i) the particular loci that contribute to repeat
family transcription differences between diseased and
healthy states, (ii) the coding capacity of transcribed re-
peat loci of possible relevance for a specific disease, and
(iii) potentially variant retrotransposon proteins and
RNAs that should be considered when studying disease
relevance. We therefore applied a recently developed
locus-specific TE mapping pipeline (PT, EP, DT, unpub-
lished data), as described in the Methods section, to re-
analyze the GSE67196 data set [171]. The numbers of
mapped loci are summarized in Additional file 1: Figure
S9A. Principal component analysis (PCA) and heatmap
plots again showed cerebellum TE expression to be as
variable within C9ALS, sALS, and control groups as




Fig. 7 Analyses of RNA-Seq datasets for TE expression. a The percentage of retrotransposon reads among total mappable reads (TEs and genes)
in the SRP064478 and GSE76220 RNA-Seq datasets. Significance was determined by Student's t-test. b The percentage of reads originating from
retrotransposons among total mappable reads in cerebellum (left) and frontal cortex (right) samples of the GSE67196 dataset. c MDS plots of the
GSE67196 dataset for TEs of C9ALS (blue), sALS (green), and control (red) samples. Samples are consecutively numbered for each group. d MDS
plot of the NeuroLINCS SRP098831 dataset for TEs of C9ALS (blue), SMA (green), and control (red) samples (left). Individual patient samples are
numbered consecutively and each replicate is given the same number. Discrete clustering of C9ALS samples is evident. Right: the percentage of
retrotransposon reads among total mappable reads for C9ALS vs control samples of the NeuroLINCS dataset
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(Additional file 1: Figure S9B, C, left). However, as
expected, clustering of frontal cortex C9ALS samples
distinct from control and sALS samples was evident
(Additional file 1: Figure S9B, C right). Supporting
Prudencio et al. [52], the greatest number of DE TE
loci (determined as having padj<0.05 and greater than
2-fold differential transcription) were identified for
C9ALS vs sALS (3963 loci), followed by C9ALS vs
controls (652 loci), and sALS vs controls (109 loci).
However, these DE TE loci comprised only 1.8%,
0.3%, and 0.06%, respectively, of a total of 2.12 x 105
TE loci mapped (Additional file 4: Table S3).
Caveats of this type of analysis should be noted. For ex-
ample, most of the significant DE L1 loci were likely not
transcribed from their own promoters, since 1) almost
95% of those mapped were less than 5600 bp in length
and so lacked much of their 5' UTRs, and 2) 70% of DE
L1s were within genes, and so may be transcribed as part
of a longer gene transcript. Moreover, only 2 younger
primate-specific L1P1 and 4 L1PA2 L1 loci were differen-
tially expressed (among a total of 164 L1P1 and 135
L1PA2 individual elements mapped). As for DE Alu loci,
81% were within genes (98% of all Alu loci being upregu-
lated). Furthermore, most mapped Alu loci were older ele-
ments, with only 5% of them AluY subfamily members, a
bias likely due to the inability of currently available algo-
rithms to confidently map short sequence reads to young
highly similar TEs. In general, designing RNA-Seq analysis
pipelines that efficiently map short sequence reads of
young highly similar TEs to their source loci has to date
been difficult for reasons discussed below.
In summary, RNA-Seq analysis of the SRP098831 Neu-
roLINCs dataset suggests widespread upregulation of TE
sequences from numerous subfamilies in C9orf72 ALS pa-
tients, as previously reported for the GSE67196 dataset
[52]. However, additional locus-specific analysis of the
GSE67196 dataset suggests that many loci contributing
mappable reads were not autonomously transcribed from
their own promoters and were likely part of longer gene
transcripts. More detailed transcription analyses targeting
a selected cohort of full-length intact intergenic TE loci
are needed to validate misregulation of retrotransposon
expression in C9orf72-associated ALS disease.
Discussion
Self-aggregation of RNA-binding proteins is a leitmotif
of neurodegenerative diseases, including amyotrophic
lateral sclerosis. The ORF1 protein of LINE-1 retrotran-
sposons is also an aggregation-prone RNA-binding pro-
tein. Of the approximately 500,000 L1s in the human
genome, about 5000 are full-length, or about one per-
cent of DNA [10, 174]. Many of these L1s have the po-
tential to be transcribed and translated, although
different tissues may express different L1s [175]. We
speculate that misregulation of even a small number of
these, leading perhaps to mislocalization and augmented
aggregation of ORF1p, could have negative effects on
some cells, including neurons. In this study, to increase
our understanding of the role of ORF1p in disease, we
extended previous investigations of its subcellular
localization and aggregation properties. We then consid-
ered potential interactions of amyotrophic lateral
sclerosis-related proteins and the ORF1p RNP and the
possibility of misregulated L1 activity in the ALS state.
Analogous to gene products associated with certain
neurodegenerative diseases, L1 ORF1p RNPs are prone
to forming cytoplasmic RNA granules. In unstressed
cells of some lines, ORF1p constitutively forms cytoplas-
mic granules that are only faintly and partially marked
by canonical stress granule proteins. As shown in Fig. 1,
stress to the cell increases both the size of ORF1p cyto-
plasmic aggregates and colocalization with SG proteins,
and deleting a Q-N-rich region of human ORF1p abol-
ishes aggregation. Furthermore, we showed here that L1
elements with a variant ORF1 R159 codon, a residue
that controls both retrotransposition and the ability of
ORF1p to seed cytoplasmic RNA aggregates, are com-
mon in the human genome. Thus, cell stress promotes
and certain sequence polymorphisms alter cytoplasmic
aggregation of L1 ORF1p.
A functional role for L1-associated cytoplasmic RNA
granules in retrotransposition remains unknown. This
begs the question, what are these constitutively
expressed ORF1p aggregates? ORF1p fails to associate
with Golgi, lysosome, or endoplasmic reticulum marker
proteins [60, 176, 177]. Endogenous ORF1p aggregates
in unstressed cells occasionally abut P-bodies but gener-
ally do not overlap ([60]; Additional file 1: Figure S1F).
Guo et al. [71] found that exogenous and endogenous
ORF1p colocalized with autophagosome marker LC3
protein in HEK 293T cells, an association that increased
with inhibition of autophagy. We here confirmed that
endogenous ORF1p granules of unstressed 2012Ep cells
are also partially marked by red fluorescent protein
(RFP)-tagged LC3 (Additional file 1: Figure S1G), but we
failed to detect their colocalization with endogenous
autophagy marker proteins ATG12 or ATG16L1
(Additional file 1: Figure S1H, I). It has also been re-
ported that ORF1p co-IPs and colocalizes in some cyto-
plasmic granules with IGF2BP1/IMP1 [124], part of a
multi-protein complex found in granules of neuronal
axons [178–180]. IMP1 granules have been reported as
distinct from P-bodies and stress granules [181]. It is
therefore possible that ORF1p aggregates in more than
one type of cytoplasmic structure.
Endogenous ORF1p may concentrate as perinuclear, nu-
clear, or nucleolar. We showed in Fig. 2 that in some cells
ORF1p also forms small nuclear foci distinct from
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nucleoli; ectopically expressed Alu and likely other RNAs
colocalize with these foci. Other studies have also reported
endogenous ORF1p nuclear localization, specifically in
some human cancer cell lines and tissues [60, 76, 77, 79,
182], and murine germline, chloroleukemia, and cardio-
myocyte cells [183–187]. Why ORF1p is cytoplasmic in
some cells and nuclear in others is unclear but suggests a
dynamic aspect of ORF1p biology that is starting to be ap-
preciated in the retrotransposon field [100].
We therefore examined the cell cycle as one possible
mechanism controlling ORF1p subcellular localization.
Blocking 2102Ep cell cycling at G1/S phase transition
did not obviously alter ORF1p nuclear localization.
Non-blocked cells showed significant concentration of
ORF1p in nucleoli, whether the cells were in G1 phase
or not. Our results in part contradict a recent study pro-
posing a strong cell cycle bias for ORF1p accumulation
in the nucleus during mitosis where it remains during
G1 phase [100]. This discrepancy may in part be due to
the fact that we queried strictly nucleolar accumulation
as the most obvious feature of ORF1p nuclear
localization in 2102Ep cells; failure to observe ORF1p in
nucleoli does not necessarily preclude its diffuse pres-
ence in the nucleoplasm. Also, the Mita et al. study
[100] tested a different cell line (HeLa) and ORF1p over-
expressed from plasmids, while here we examined en-
dogenous ORF1p localization as more biologically
relevant. Indeed, 2102Ep cells mimic early human em-
bryogenesis, where heritable L1 insertions accumulate
[69, 168], while HeLa cancer cells mimic L1 activity in
human cancers. While both cellular niches are known to
support L1 retrotransposition, it stands to reason that
differences may exist with respect to L1 regulation.
Thus, the mechanisms that control L1 ORF1p nuclear
localization clearly require further investigation in a
range of cell lines and with care paid to their growth
conditions (for as noted above, the frequency of ORF1p
nucleolar localization varies with 2102Ep cell density).
Previously, we showed that ORF1p point mutations
and C-terminal and N-terminal deletions increased nu-
clear accumulation (see text and Supplemental data of
[60]). Thus, maintaining the integrity of ORF1p struc-
ture seems to be important for cytoplasmic retention
and aggregation. Furthermore, concentration of ORF1p
at the nuclear membrane of some cells (Fig. 2), its re-
ported RNA-dependent association with karyopherin
subunit alpha 2 (KPNA2; [124]), and the detection by
mass spectrometry of importin 7 (IPO7) within an
ORF2p complex [141], suggest that L1 RNPs interact
with the nuclear import machinery. Indeed, it was re-
cently shown that loss of transportin 1 (TNPO1), the
beta subunit of the karyopherin receptor complex, re-
duces nuclear localization of epitope-tagged ORF1p
[188]. It was also recently proposed that ORF1p
expression is required for nuclear ORF2p localization
[141]. However, this is not supported by our earlier find-
ings that ORF2p overexpressed alone efficiently enters
nucleoli of human osteosarcoma 143B TK- cells; at that
time we also mapped a functional nuclear localization
signal to the N-terminus of ORF2p [76].
Might there be cellular consequences for misregulated
expression or mislocalization of aggregation-prone
LINE-1 proteins? L1 ORF1p is a promiscuous
RNA-binding protein able to capture many cellular RNAs.
Co-IP experiments with tagged L1 RNPs have identified
numerous bound RNAs, including SVA and Alu SINEs
and small non-coding RNAs of importance for the cell
[124, 189]. Direct co-IP experiments also confirmed over
60 proteins that associate with tagged L1 ORF1p RNPs,
mostly in an RNA-dependent manner [60, 73, 124, 190].
Among these were several RNA-binding proteins associ-
ated with ALS and FTLD, including FUS, HNRNPA1,
HNRNPA2B1, and TDP-43. As we have shown here,
pathogenic mutants of ALS proteins FUS, SOD, and
TDP-43 also colocalize with ORF1p in cytoplasmic RNP
aggregates. As with certain neurodegeneration-associated
proteins, increased expression or mislocalization of
ORF1p, whether through mutation or loss of L1 suppres-
sion, could seed protein aggregation, co-sequester other
cellular proteins or RNAs, disrupt normal patterns of pro-
tein degradation or RNA processing, and trigger cytotox-
icity. Retrotransposon-encoded proteins can also induce
cellular stress responses. Gasior et al. [191] showed that
overexpression of L1 ORF2p causes double-strand
chromosome breaks. These results are consistent with ob-
servations that L1 overexpression can induce apoptosis
and senescence or potentially an immune response in
some cell lines [192–195]. Perhaps these are reasons for
the evolution of so many cellular factors that restrict L1
activity [42].
Previous studies have considered links between
TDP-43 and retrotransposon expression. TDP-43 was
first identified as a transcriptional repressor that binds
the RNA regulatory element TAR of HIV-1 proviruses to
inhibit their expression [196]. However, a role for
TDP-43 in regulating HIV or HERV transcription is not
clear [197]. Douville et al. [49] found expression of
HERV-K(HML2) pol and TARDBP genes to be strongly
and positively correlated, and their encoded proteins
colocalized in ALS neurons. Douville and Nath [198]
also linked TDP-43 with altered HERV-K(HML-2) RT
expression in brain tissues. Data-mining rodent and hu-
man interaction experiments, Li et al. [137] found that
TDP-43 protein targets and binds LTR and non-LTR TE
transcripts and that this association is reduced in cor-
tical tissues of FTLD patients. Furthermore, reanalysis
of RNA-Seq datasets of human TDP-43 overexpressed
in transgenic mice [199] and endogenous TDP-43
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depleted in mouse striatum [200] showed a general in-
crease in expression of LTR, non-LTR and DNA TEs
under both conditions, with concordance between TE
transcripts upregulated and those bound by TDP-43
protein [137]. While it was reported [51] that TDP-43
protein bound the HERV-K LTR with an attendant in-
crease in HERV-K(HML-2) transcription and RT activity,
Manghera et al. [138] found wild-type TDP-43 bound
the HERV-K(HML-2) promoter without activating its
transcription, while overexpressed ALS-associated TDP-43
mutants promoted HERV-K(HML-2) protein aggregation
and clearance from astrocytes (but not neurons) by stress
granule formation and autophagy. Overexpression of a hu-
man TDP-43 transgene in Drosophila was accompanied by
motor problems and derepression of retrotransposons in
general and glial cell-specific upregulation of gypsy ele-
ments in particular, along with an increase in programmed
cell death induced by DNA-damage [139].
We found that, while TDP-43 binds and colocalizes
with the L1 ORF1p RNP, its increased expression
strongly represses rather than derepresses human L1
and mouse IAP cell culture retrotransposition (without
attendant cytotoxicity). On the other hand, inhibition of
endogenous TDP-43 had no effect on L1 retrotransposi-
tion in HEK 293T cells. Although altered levels of
TDP-43 were associated with modestly increased methy-
lation of endogenous L1 promoters, this was not accom-
panied by a change in exogenous ORF1p expression or
promoter effects in a luciferase assay. Moreover, a recent
study by Prudencio et al. [52] found no significant asso-
ciation between levels of TDP-43 RNA or protein and
TE expression in frontal cortex samples of a large cohort
of ALS/FTLD patients. Our reanalysis of two RNA-Seq
datasets [147, 148] also failed to detect strong
TDP-43-specific changes in expression of retroelement
subfamilies in cell lines depleted of endogenous TDP-43
protein. Therefore, a role for TDP-43 protein in aberrant
retroelement activity begs further investigation.
We also reanalyzed for TE subfamily expression two
RNA-Seq datasets of sALS tissue samples not previously
examined for TE expression (GSE76220 and SRP064478)
and one previously tested dataset of both C9orf72 and
sporadic ALS tissue samples (GSE67196). In all three
datasets, we failed to find significant misregulation of TE
subfamilies in sALS vs controls, consistent with the pre-
vious analysis of GSE67196 [52] and with our RT-qPCR
and Western blot analyses of ALS and control brain and
spinal cord tissues. However, our analysis of a Neuro-
LINCs dataset (SRP098831) found both SMA and
C9ALS vs non-ALS patient-derived iPSC cell lines differ-
entiated to motor neurons to have significant numbers
of DE TEs, including young SINE Alu subfamilies: this
was in line with the previous findings of Prudencio et al.
[52] that TE expression is misregulated in C9ALS vs
sALS samples of the GSE67196 dataset. However, our
locus-specific analysis of the GSE67196 dataset suggested
that many of the reads contributing to the retrotransposon
subfamily analyses did not originate from TE sequences
transcribed from their own endogenous promoters but ra-
ther from sequences contained within longer transcripts.
Several pitfalls exist for RNA-Seq analyses of differen-
tial TE expression: conclusions should be drawn with
care. High copy number, close sequence similarity, and
especially the frequent embedment of TE sequences in
longer gene transcripts (i.e., exonization) can lead to
misinterpretation. While expression of a TE subfamily
may appear misregulated, a change in expression ob-
served may in fact be due to altered expression of a gene
in which a member of that TE subfamily resides. In their
analysis of RNA-Seq data from HEK 293T cells, for ex-
ample, Deininger et al. [174] mapped greater than 99
percent of L1-derived sequence reads within other RNAs
unrelated to retrotransposition. Moreover, bona fide L1
transcripts originating from L1 5' UTR promoters were
limited to only a small number of highly expressed
full-length L1 loci.
Furthermore, we have speculated that cell conditions
that induce elevated expression of L1s or HERVs, and
therefore their encoded reverse transcriptases, could in-
duce promiscuous reverse transcription of cytoplasmic
RNAs ([42], see also [201]). Indeed, a recent report has
demonstrated the accumulation of cytoplasmic L1-related
ssDNAs in neurons derived from hESCs lacking the exo-
nuclease TREX1, a gene mutated in Aicardi-Goutières
syndrome patients [195, 202]. The ectopic cytoplasmic
cDNAs so generated would be amenable to amplification
during RNA-Seq or RT-qPCR protocols and so bias up-
wards estimates of expression from their source loci. Al-
though as yet an unverified concern, recent studies have
reported elevated levels of TE-derived cytoplasmic cDNAs
or hybrid RNA/DNA molecules in cancer and other dis-
ease states [195, 201, 203]. The retrotransposon field is
working to control such possible sources of error when
interpreting TE expression data [174, 175]. In general, fur-
ther improvements in transcriptomics, and especially
single-cell based approaches, will eventually clarify the de-
gree of deregulation of TE expression in ALS and other
neurodegenerative disorders.
Conclusions
In considering links between retrotransposon expression
and neurodegenerative conditions, we expanded previ-
ous knowledge of the aggregation properties of the
LINE-1-encoded ORF1 protein and factors that control
its accumulation. We also presented data that the cell
cycle does not strongly alter nuclear localization of en-
dogenous L1 ORF1p in nullipotent embryonal carcinoma
cells. We showed that some ALS-associated protein
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mutants associate with ORF1p in cytoplasmic aggregates
and that increased expression of some ALS-linked pro-
teins limit LINE-1 retrotransposition. We emphasized
especially TDP-43, a protein that accumulates in the
cytoplasm of a majority of ALS patients, but failed to
find consistent evidence in cell culture for an effect on
retrotransposon activity, in contrast to some previous
reports.
By means of RT-qPCR and Western blotting of ALS
tissues and reanalysis of available RNA-Seq datasets, we
also sought a link between sporadic ALS and retrotrans-
poson misregulation. In sum, clear-cut evidence is so far
lacking for involvement of non-LTR retrotransposon ex-
pression in sALS. Using the same tissue samples as in
the present study, we also recently profiled transcription
of HERV-K(HML-2) and HERV-W LTR retrotranspo-
sons by direct Sanger sequencing of cloned cDNAs and
RT-qPCR and Western blot analyses, but failed to find
significant differences when comparing ALS and con-
trols [204]. It is conceivable that previous observations
of differential TE expression levels may relate to altered
global DNA methylation status and other epigenetic
changes observed in some ALS patients [205–208],
which could in consequence cause selected TE loci to
be differentially transcribed. At least, analyses of add-
itional C9orf72-mutated ALS RNA-Seq datasets seem
warranted. We believe examining neurodegenerative
disease-affected tissues for perturbations in the aggre-
gation dynamics of L1-encoded proteins could also
prove informative. It is also reasonable to continue to
apply improving methods of next-generation sequen-
cing analysis to examine neurodegenerative and other
brain diseases for misregulated activity of TEs in
general and the L1 in particular, a mobile element with
hundreds of thousands of copies and which through
long evolution has been directly responsible for
generating over a quarter of the DNA in the human
genome [209].
Methods
Plasmid and RNAi constructs
Plasmid constructs were kindly provided by the following
researchers: 3xFL-FUS-WT, 3xFL-FUSL-R525L, 3xFL-
FUSH-R514G, 3xFL-FUSQ-H517Q, and 3xFL-FUSQ-
R521H (J. Manley, Columbia University; [210]); pcDNA5
FRT/TO (G4C2)31 (M. Cozzolino, University of Rome "Tor
Vergata"; [96]); GFP-(GA)50 (L. Petrucelli, Mayo Clinic,
Florida; [131]); IAP-neoTNF (M. Dewannieux, Institut
Gustave Roussy; [144]); pmRFP-LC4 (T. Yoshimori,
Addgene 21075); pEGFP-C1-MK2-mut T205/317E (M.
Gaestel, Medical School Hannover, Germany; [111]);
pcDNA3 3XFL-OPTN-E50K (H. Kawakami, Hiroshima
University; [211]), mCherry-PSP1 (D. Spector, Cold
Spring Harbor Laboratory; [212]); EGFP-TDP-43-WT,
EGFP-TDP-43-A315T, EGFP-TDP-43-K82/84A (B.
Wolozin, Boston University; [213]); pRK5-Myc-TDP-43
(J. Wang, Johns Hopkins University, [214]); SOD1
WT-Tomato, SOD1 A4V-Tomato, SOD1 G93A-Tomato
(J. Yerbury, University of Wollongong; [215]), pCS2
(+)MT UBQLN2 WT2 (Myc-UBQLN2), and pCS2 (+)MT
UBQLN2 P497H (D. Ito, Keio University School of
Medicine; [216]). The following plasmids have been previ-
ously described: 99-PUR-RPS-EGFP, 99-PUR-JM111-EGFP
[87], ORF1-T7-L1RP, ORF1p-EGFP, HNRNPA1-RFP [60],
ORF1-EGFP-L1-RP, pBS 7SL Alu-MS2 (Ya5), pcDNA
SVASPTA1-MS2, ORF1-WT-GFP [72], and pc-L1-1FH [124].
Ultimate ORF cDNA clones (Invitrogen) were cloned
with V5-epitope tags and tobacco etch virus (TEV) pro-
tease cleavage sites on their N-termini by shuttling
them from pENTR221 vector into pcDNA3.1/nV5-
DEST vector using Gateway Technology (Invitrogen).
Ultimate ORF Clone ID numbers were V5-ALS2 (IOH
62502), V5-ANG (IOH29453), V5-OPTN (IOH57143),
V5-SMN2 (IOH10903), V5-SOD1 (IOH4089), V5-SQS
TM1 (IOH5103), V5-TAF15 (IOH40855), V5-TBK1
(IOH21006), V5-VAPB (IOH4934), and V5-VCP (IOH
52832). FL-TDP-43 was generated using Ultimate ORF
Clone IOH45677 and Gateway vector pEZYflag (Y.-Z.
Zhang, Addgene 18700). TDP-43-V5-WT and TDP-43-FL
were generated by PCR-amplification of TDP-43 from
pRK5-Myc-TDP-43 with AAG linker and C-terminal V5-
and FLAG-tags, respectively, and cloned in pcDNA6/
myc-His B (pcDNA6, Invitrogen). C9ORF72-FL with
AAG linker and C-terminal FLAG tag was amplified from
Ultimate ORF Clone IOH45695 and cloned in pcDNA6/
myc-His B.
The helper-dependent adenovirus for construct A/
RT-pgk-L1RP-EGFP (Ad-L1) [97, 217] was prepared as
described [218]. N1-EGFP was from Clontech. The
pc6-RPS-EGFP-ΔCMV retrotransposition reporter con-
struct included full-length L1-RP and the EGFP re-
porter cassette in a modified version of pcDNA6/
myc-His B vector lacking a cytomegalovirus (CMV)
promoter. PCR and QuickChange mutagenesis methods
were used to generate ORF1-EGFP-L1-RP-R159H
(from ORF1-EGFP-L1-RP), ORF1-EGFP-L1-RP-LKEA
AAAAL, ORF1p-Δ179-205-GFP (from ORF1p-EGFP),
LKELLKEAL-EGFP (from N1-EGFP), V5-ANG-H37R
and V5-ANG-H138R (from V5-ANG), V5-TBK1-S172A
and V5-TBK1-E696K (from V5-TBK1), and pc6-RPS-
EGFP-ΔCMV-R159H (from pc6-RPS-EGFP-ΔCMV).
siRNAs (Additional file 1: Figure S5A) were synthe-
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Cell culture and tissues
Human 2102Ep embryonal carcinoma cells (a gift from
P.K. Andrews, University of Sheffield), human cervical
cancer HeLa-JVM cells [219], human embryonic kidney
(HEK) 293T cells (ATCC), human embryonic fibroblasts
(HEFs, ATCC), and mouse hybrid motor neuron
NSC-34 cells (a gift from D. Griffen, JHU) were grown
in Dulbecco’s modified Eagle’s medium (DMEM).
SH-SY5Y cells (ATCC CRL-2266) were grown in
DMEM/F12 (Ham) medium (Gibco) and human
SK-N-SH cells (a gift from D. Valle, Johns Hopkins Uni-
versity) were grown in Eagle's Minimum Essential
Medium. Medium was supplemented with 10% FBS
(Hyclone or Sigma), GlutaMax, and Pen-Strep (Invitro-
gen). Plasmid and siRNA transfections used FuGENE
HD (Promega) or Lipofectamine 3000 (Thermo Fisher
Scientific) reagents. H9 human ESCs [167] were ob-
tained from Wicell (RRID: CVCL_9773) and cultured
and passaged as previously described [168].
Post-mortem brain and spinal cord frozen tissues were
obtained from the University of Maryland Brain and Tis-
sue Bank of the NIH NeuroBioBank, the Target ALS
Multicenter Postmortem Tissue Core at Johns Hopkins
University, and the Department of Neurosciences of the
University of California San Diego School of Medicine,
as indicated in Additional file 3: Table S2. All tissues
were obtained following approval of the Institutional
Review Boards of the UCSD School of Medicine (to JR)
and the JHU School of Medicine (IRB00066246 to JLG).
Immunofluorescence and microscopy
Commercial antibodies included rabbit (rb) α-ATG12
(D88H11), rb α-ATG16L1 (D605), rb α-CDT1 (D10F11),
rb α-cyclin B1, mouse (ms) α-DYKDDDDK (FLAG)-tag
(9A3) (all Cell Signaling Technology), goat
(gt) α-eIF3η (N-20, Santa Cruz), rb α-Geminin (Cell Sig-
naling Technology or ab195047, Abcam), ms α-p70 S6
kinase (which recognizes HEDLS/EDC4; [220]) (H-9,
Santa Cruz), rb α-Myc-tag (71D10, Cell Signaling Tech-
nology), ms α-TDP-43 (10782-2.AP, Proteintech), gt
α-TIA1 (C-20, Santa Cruz), ms α-T7-Tag (Novagen), ms
α-TLS (FUS) (BD Transduction Laboratories), rb
α-β-tubulin-2 (Pierce), and ms α-V5-tag (Invitrogen).
Purified ORF1p antibodies included rb polyclonal
α-ORF1p-AH40.1 (4292) (a gift from M. Singer, Carne-
gie Institute for Science; [68]), rb monoclonal
α-JH73-ORF1 (from J. Han, Tulane University and K.
Burns, Johns Hopkins University; [177]), rb polyclonal
α-V14-ORF1 (a gift from C. Harris, The Verto Institute;
[182]) and ms α-4H1-ORF1 (from K. Burns, and Milli-
pore MABC1152; [67]). Human α-ANA-N was obtained
from a patient with autoimmune disease [76]. Donkey
Cy3-, DyLight 488-, DyLight 549-, Alexa Fluor 594-, and
peroxidase-conjugated secondary antibodies were from
Jackson ImmunoResearch Laboratories.
Western blotting, IF, and RNA FISH were performed
as described [60, 72]. All Western blots were run on
NuPAGE 4-12% Bis-Tris gels (ThermoFisher). Cells were
examined using a Nikon Eclipse Ti-A1 confocal micro-
scope with NIS-Elements AR software.
Whole-cell protein and RNA extraction
For protein extracts, tissues or cells were lysed in RIPA
buffer (Sigma) with Mammalian Protease Inhibitor
Cocktail and phenylmethanesulfonyl fluoride (Sigma)
and homogenized with a Diagenode Bioruptor. In the
case of tissues, 2 mm zicronium silicate beads (Next
Advance) were added to the tubes. Samples were centri-
fuged at 11K at 4oC for 15 minutes to recover super-
natant and resuspended in 3X SDS loading buffer.
Isolation of HEK 293T cell nuclear and cytoplasmic
extracts utilized the NE-PER kit (Thermo Scientific).
For RNA extracts, all brain tissue and some spinal
cord tissues were disrupted and homogenized in 500 ml
of Trizol (Invitrogen) using the TissueLyser LT (Qiagen).
Briefly, 30 mg of sample were transferred to a 2 ml tube
containing 250 μl of Trizol and one 5 mm stainless steel
bead. The TissueLyser LT program used was 50Hz for 1
min. After a spin, the supernatant was collected and an-
other 250 μl were added to the sample to repeat the
same procedure. Finally, both fractions were combined
and RNA purification with Trizol followed the manufac-
turer`s instructions. Some spinal cord samples were ho-
mogenized in 500 μl of Trizol and zicronium silicate
beads using a Benchmark BeadBlaster24. Following cen-
trifugation, the supernatant was further purified using
an RNeasy Mini Kit with On-column DNase digestion
with RNase-Free DNase Set (Qiagen).
Next, the RNA was treated with RQ1 RNase-free
DNAse (Promega) for 30 min, purified with ultrapure
phenol:chloroform:isoamyl alcohol mixed at 25:24:1 (v/
v/v) (Ambion) and precipitated with 3 volumes of ice
cold 100% ethanol and 0.1 volume 3M sodium acetate.
To assure absence of cross-contaminating genomic
DNA, 1 μg of total RNA was treated again with another
round of RNase-free DNase I (Invitrogen) for 15 min.
RNA Integrity numbers (RINs) are shown in
Additional file 3: Table S2 (range: 2.1-10; median 6.6).
RNA integrity numbers (RINs) were determined using
an Agilent BioAnalyzer and Agilent RNA 6000 Nano Kit
following the manufacturer's recommendations. We at-
tribute low RIN numbers in some samples to long
post-mortem intervals affecting tissue quality and to the
rigorous DNase-treatments of RNA that were required
to remove residual contaminating genomic DNA, a
strategy necessary for our sensitive PCR amplification of
multi-copy repeat cDNAs. To assess effects of RNA
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quality on our analyses we plotted RIN values versus
RT-qPCR Ct-values of GAPDH and could detect no sig-
nificant effect of RIN when the various tissue types were
considered separately. However, a mild effect (R2=0.38)
of RNA quality on Ct-levels is acknowledged when com-
bining RIN and Ct values from all samples. Importantly,
omission of samples with lower RINs did not affect our
conclusions.
Retrotransposition assay
The EGFP L1 cell culture retrotransposition assay was
conducted as previously described [87, 221, 222]. The
IAP retrotransposition assay was carried out essentially
as described in [144]. One μg of IAP-neoTNF element re-
porter plasmid was cotransfected with 0.5 μg of empty
vector or test plasmid in HeLa-JVM cells. At eighteen
hours post-transfection, the cells were expanded from
six-well plates to T75 flasks, and two days later selection
for retrotransposition events with 500 μg/ml of G418
was begun. After 15 days of selection, cells were fixed,
stained with Giemsa, and colonies were counted.
SH-SY5Y and NSC-34 cells were infected with Ad-L1
at ∼8 × 1012 viral particles/mL [97, 217].
Bisulfite experiments
Bisulfite analysis was performed as described [21, 146]
using the EZ DNA Methylation Gold Kit (Zymo Research).
The analyses of Additional file 1: Figure S2 queried by
PCR the methylation status of 9 CpGs within a 436-nt
stretch (1169-1604) of L1 ORF1 surrounding the R159




cons analyzed for Additional file 1: Figure S6 spanned 363
nts of the L1 5' UTR containing 17 CpG dinucleotides;
primers were For (AAGGGGTTAGGGAGTTTTTTT)
and Rev (TATCTATACCCTACCCCCAAAA). PCR prod-
ucts were subcloned (TOPO TA Cloning Kit, Invitrogen),
sequenced, and analyzed with the QUantification tool for
Methylation Analysis, QUMA (quma.cdb.riken.jp; [223]).
The significance of methylation differences was examined
with Fisher's Exact Test statistics generated by QUMA.
Assessment of toxicity
To test potential protein toxicity (Additional file 1:
Figure S4), we co-transfected in HeLa-JVM cells
pcDNA6/myc-His B, a blasticidin S-resistance gene
(bsr)-containing vector, together with empty vector
(pcDNA3) or test expression constructs. On day 2, cells
were expanded to T75 flasks and selection with 5 μg/ml
blasticidin was begun. After 12 days, cells were fixed,
stained with Giemsa and colonies were counted. Simi-
larly, we co-transfected in HeLa cells pcDNA3, a
neomycin (neo)-resistant vector, together with either
empty vector (pcDNA6/myc-His B) or test expression
constructs, followed by selection of cells with 500 μg/ml
Geneticin (G418, Thermo Fisher).
Trypan Blue exclusion assays were performed in HEK
293T cells. Following staining, live and dead cells were
counted using a Countess II Automated Cell Counter
(Thermo Fisher Scientific). Use of the MultiTox-Fluor
Multiplex Cytotoxicity Assay kit (Promega) followed
manufacturer's instructions. This assay simultaneously
measures cell viability and cytotoxicity in a
single-reagent reaction, permitting ratios of live to dead
cell readings to be calculated.
RT-qPCR
RT-qPCRs were conducted as previously described [146,
224]. A High-Capacity cDNA Reverse Transcription Kit
(Applied Biosystems) was used to generate cDNA.
RT-negative controls were run in parallel for all qPCR
reactions. Duplicate samples were analyzed in a StepOne
Real-Time PCR system (Applied Biosystems) using
GoTaq qPCR Master Mix (Promega) and PCR primers
at 200 nM each. We used two sets of primers to analyze
endogenous L1 expression directed against L1Hs ORF1
(N-51-Fwd: GAATGATTTTGACGAGCTGAGAGAA;
N-51-Rev: GTCCTCCCGTAGCTCAGAGTAATT) or
L1Hs ORF2 sequence (N-22 Fwd: CAAACACCG
CATATTCTCACTCA; N-22 Rev: CTTCCTGTG
TCCATGTGATCTC). We also analyzed expression of
AluS (AluS-Fwd: GCCGAGGCGGGCGGATCACC;
AluS-Rev: GCCTCCCGAGTAGCTGGGAT) and AluY
(AluY-Fwd: AGATCGAGACCATCCTGGCT; AluY-Rev:
CCGCCTCCCGGGTTCACGCC). In all the cases,
GAPDH was used as an internal normalization control
(primers: GAPDH-Fwd: TGCACCACCAACTGCTTAG
C; GAPDH-Rev: GGCATGGACTGTGGTCATGAG).
qPCR cycling parameters were as follows: 10 min at
95°C, 40 cycles of 15 sec at 95°C, followed by 60 sec at
60°C. Melting curve analysis was performed to confirm
the identity of the amplified product. We employed the
ΔΔCt method [225] to determine relative differences in
transcript levels. L1 and Alu transcript levels were plot-
ted as "Fold change in transcript level" with respect to
the transcript level in H9-hESCs (=1). Standard devia-
tions were calculated based on 4 data points per sample
derived from duplicate measurements and a technical
replicate for each sample.
RT-PCR reactions used GoTaq Green Master Mix (Pro-
mega) and primer pairs 1) L1 5'UTR forward (ACGG
AATCTCGCTGATTGCTA) and L1 5'UTR reverse
(AAGCAAGCCTGGGCAATG) [226], which amplify a
98-bp fragment of L1 5' UTR, 2) ORF1-fwd (AGGA
AATACAGAGAACGCCACAA) and ORF1-rev (GCTG
GATATGAAATTCTGGGTTGA), which amplify a
Pereira et al. Mobile DNA            (2018) 9:35 Page 22 of 30
259-bp fragment of L1 ORF1, and 3) GACTBPAIR2-FOR
(TTCCAGCCTTCCTTCCTG) and HACTBPAIR2-REV
(AATGATCTTGATCTTCATTGTGC), which amplify a
207-bp fragment of actin beta. PCR conditions were 2 min
at 95°C, 30 sec at 95°C, 1 min at 58°C, 30 sec at 72°C for
35 cycles, followed by 1 min at 72°C.
Bioinformatic analysis
Occurrence of R159 polymorphisms in human L1 elements
L1Base 2 [13] was used for counting R159
polymorphism-containing human L1 elements. In brief,
chromosome coordinates for human Full-Length, Intact
LINE-1 elements (FLI-L1), human ORF2 Intact LINE-1 ele-
ments (ORF2-L1), and human Full-Length >4500nt LINE-1
elements (FLnI-L1) (Ens84.38) were obtained from L1Base
2. Corresponding sequences of L1 elements were retrieved
using UCSC Table Browser [227]. Sequences of each subset
were multiply aligned using MAFFT online [228] or as im-
plemented in Geneious (Biomatters Ltd.; https://www.ge-
neious.com; [229]). Occurrences within L1 ORF1 of a codon
for R159 and its non-synonymous variants, including the
most frequently observed codons for histidine (H), cysteine
(C) or proline (P), were counted and their respective per-
centages calculated. Only a subset of the 13,671 L1 elements
in the FLnI-L1 dataset were multiply aligned due to limita-
tions of both the local and online versions of MAFFT. Also
for the FLnI-L1 dataset, which included a greater number of
evolutionarily older L1 sequences, a minority of aligned L1
sequences displayed structural rearrangements and/or
higher sequence divergence in the R159 codon region result-
ing in unreliable prediction of sequence at the R159 codon
position: these were excluded. In all, 6346 FLnI-L elements
were included in the analysis.
RNA-Seq datasets
Publicly available RNA-Seq datasets were analyzed by
TEtranscripts software package [150]. TDP-43-related
datasets SRP057819 and GSE77702 have been previously
described [147, 148]. Dataset SRP064478, submitted by
the Bennett Lab at Virginia Commonwealth University,
consists of RNA-Seq data for total stranded RNA with
>50 million 2x150 bp sequencing reads from 15 post-
mortem cervical spinal cord sections (7 ALS and 8
healthy controls). GSE76220 includes 20-30 million
mappable 1x50 bp reads from total stranded RNA iso-
lated from laser capture microdissected motor neurons
from post-mortem lumbar spinal cords [172]. GSE67196
consists of on average 83 million 1X100 bp reads per
sample (91.5 million for cerebellum and 73.6 million for
frontal cortex), as described by [52, 171].
The Library of Integrated Network-Based Cellular Signa-
tures (LINCS)-NeuroLINCS dGAP dataset (accession num-
ber phs001231.v1.p1, SRP098831) includes RNA-Seq of
iPSC-derived motor neurons from 4 C9ALS and 3 SMA
patients (3 sequencing replicates each), and 3 unaffected
healthy controls (2 or 3 replicates each). It has been reported
that L1 activity in iPSCs can vary with cell passage, increas-
ing during reprogramming but subsequently subsiding [224,
226, 230]. However, passage numbers of the NeuroLINCs
cell lines fall within similar ranges, from 25 to 27 for ALS
and healthy control and 21 to 30 for SMA samples.
Generating RPKM plots
To generate RPKM plots, raw data was aligned to the con-
sensus sequences for a selected group of younger retro-
transposons present in RepBase [152], including L1-Ta,
L1PA2, L1-pre-Ta, AluYa5, AluYa8, AluYb8, AluYb9, AluY,
AluSq, SVA_D, SVA_E, SVA_F, LTR5_Hs, and LTR7Y sub-
families. Alignments were made using Bowtie 2 [231] with
end-to-end sensitive parameters: -D 15 -R 2 -N 0 -L 22 -i
S, 1, 1.15. We adapted the RPKM formula to provide a
normalized measure of the number of reads that align
with each consensus sequence based on their size. Data
were plotted using OriginPro (OriginLab Corp.) with
standard deviation error bars for replicates.
MDS plots were generated in R script using the edgeR
package [232].
Use of TEtranscripts
TEtranscripts is a software package that estimates both gene
and TE transcript abundances in RNA-Seq data and con-
ducts differential expression analysis on the resultant count
tables [150]. Sequences were aligned to human genome as-
sembly GRCh38 using STAR [233]. Alignment parameters
were outFilterMultimapNmax100 and winAnchorMulti-
mapNmax 200, which allow up to 100 alignments per read.
TE annotation files were downloaded from http://labshar-
e.cshl.edu/shares/mhammelllab/www-data/TEToolkit/ (in-
cluding 1181 TE types). Following the generation of a count
table for gene and TE transcripts, the differential expression
analysis closely followed the DESeq2 package [234] for mod-
eling the counts data with a negative binomial distribution
and computing adjusted P-values. In addition to the stand-
ard transcript abundance normalization approach used by
the DESeq2 package, TEtranscripts offers two additional op-
tions, reads per mapped million (RPM) and quantile
normalization. All other procedures exactly followed the
DESeq2 method. TEtranscripts runs the DESeq2 method
with a default set of general parameters. When there were
no (or very few) replicates, we used the blind method for
variance estimation and fit-only for SharingMode. Other-
wise, we used pooled or per-condition methods and max-
imum SharingMode, as suggested by the DESeq2 package.
Locus-specific mapping of TEs
The pipeline to map TEs to individual genomic loci used
the alignment algorithm HISAT2 [235] to map sequence
reads to the human genome. Reads that mapped to more
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than one genomic position were discarded. Counts per TE
integrant (genomic loci) were generated using the multi-
BamCov tool from the BEDtools software [236]. Normalisa-
tion for sequencing depth was performed using voom
[237], with total number of reads on genes as size factors.
RepeatMasker 4.0.5 (Library 20140131), a newer version
than RepeatMasker 4.0 used by Prudencio et al. [52], was
used to generate a list of TE subfamilies. In the case of
HERVs, we re-assembled fragmented internal and LTR se-
quences to generate full-length HERV integrants: this step
avoids bias in counts due to the highly fragmented nature
of the annotated HERVs. We removed from our analyses
very small and abundant repeats (low complexity and sim-
ple repeats). Any TEs with a low number of reads across all
samples or which overlapped exons were also omitted from
our analyses. Differential expression was performed as im-
plemented in the voom library of Bioconductor [238]. A TE
locus was considered to be differentially expressed if its fold
change was greater than 2 and FDR smaller than 0.05. The
Benjamini-Hochberg procedure was used to compute the
FDR. Hierarchical clustering of the heatmap was performed
with Pearson correlation as distance and complete agglom-
eration method for both, rows and columns. Any raw data
files will be provided upon request to the authors.
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